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Abstract
Recent data in 28 U.S. states revealed that opioid use during pregnancy had increased by four
times since 2014, going from 1.5 to 6.5 per 1,000 admissions. The use of opioids during
pregnancy is dangerous to the mother and developing fetus, greatly increasing the risk for
maternal death, miscarriage, and premature birth. The increase in the number of women with
opioid abuse disorder (OUD) is reflected by a fivefold increase of infants born with neonatal
abstinence syndrome (NAS), a withdrawal syndrome from opioids. Corresponding with U.S.
trends, a community hospital in the Texas Gulf Coast region has seen an increase in pregnant
women with OUD who are being treated during pregnancy with medical avoidance therapy
(MAT). These women are being lost to follow up in the postpartum period, creating an increased
risk for relapse and recidivism. The gap in practice is that there is no formal, comprehensive
program for postpartum follow-up of women treated for OUD delivering in this facility. The
purpose of this DNP project was to utilize a multidisciplinary team to design a set of program
guidelines for a comprehensive postnatal follow-up program for women with OUD who were
treated with MAT during pregnancy. The theoretical model is the opponent process theory of
addition. These guidelines may be used by the maternal-child professionals to decrease the
relapse rates of mothers and to improve the maternal-child bonding process.
Keywords: buprenorphine; follow up; methadone; medication assisted treatment;
medication avoidance therapy; neonatal abstinence syndrome; opioid use disorder; pregnancy;
postpartum; relapse prevention; substance use disorder
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Chapter 1: Introduction
Opioid use disorder (OUD) is found throughout all gender, socioeconomic, and cultural
groups across the United States. Also frequently referred to as opioid abuse, opioid dependence
or opioid addiction, OUD is an uncontrollable pattern of using opioids without the ability to stop,
which results in impaired psychosocial functioning and inability to fulfill normal obligations
(Centers for Disease Control and Prevention [CDC], 2019a). Opioid disorder involves illegal
drugs such as heroin, illicit use of opioid pain relievers such as morphine and codeine, and the
misuse of commonly prescribed opioid pain relievers (POPRs) such as hydrocodone, oxycodone,
and codeine (CDC, 2019a). The opioid crisis has been declared a public health emergency by the
Secretary of the United States Health and Human Services (HHS) department at the request of
President Trump, authorizing aggressive action in the treatment and recovery efforts of OUD
(HHS, 2017).
Over two million people were reported to have OUD in 2018 (CDC, 2018b; HHS, 2019).
In the same year, 9.9 million people in the United States reported misusing prescription opioids,
ranking opioid misuse as one of the top two common forms of substance abuse in the country
(Substance Abuse and Mental Health Services Administration [SAMHSA], 2019b). The severity
of OUD in the nation has drastically affected mortality rates over the past 18 years. Of the
70,200 plus deaths that occurred due to drug overdose in 2017, over 47,700 resulted from opioid
use; this data indicates a six-fold increase over opioid overdose deaths reported in 1999 (CDC,
2018b).
Opioid use in women is rising and has been declared a national epidemic that is
detrimental to the country’s future. In 2015, 57% of the 2.1 million people in the population with
opioid misuse were women (Brogly et al., 2018). Women make up 65% of the prescribed users
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for POPRs, with women being 40% more likely than men to develop OUD from persistent use
(National Women’s Health Network [NWHN], 2018; Pacira Pharmaceuticals, Inc., 2017).
Programs for opioid treatment have shifted from having an 80% male-dominated population in
the 1960s to a predominately female population reported in 2010 (Krans & Patrick, 2016). In
2010 alone, over 200,000 women sought treatment for OUD through emergency departments
(EDs), with a ratio of one POPR related death for every 30 visits (CDC, 2013). From 1999 until
2010, prescription opioid overdose in women increased by 400%, resulting in an average of as
many as 18 deaths each day (CDC, 2018b; Lind et al., 2017). A 10.6% increase in opioid
overdose-related deaths in women occurred from 2016 to 2017, resulting in over 15,000 deaths
(Scholl et al., 2019).
Recent data from 28 states revealed that opioid use during pregnancy had increased by
four times since 2014, going from 1.5 to 6.5 per 1,000 admissions (Haight et al., 2018). The
actual number of pregnant women in the general population affected by the opioid epidemic is
considered much higher since this particular study did not include the 50% of births not covered
by Medicaid, the report of illicit opioid use, or births resulting in miscarriage or fetal demise
(Haight et al., 2018). The use of opioids during pregnancy is dangerous to the mother and
developing fetus, greatly increasing the risk for maternal death, miscarriage, premature birth,
congenital birth defects, and other physiological problems for the infant (American College of
Obstetricians and Gynecologists [ACOG], 2017; Carter et al., 2019; Park et al., 2012). The
increase in the number of women with OUD is reflected by a fivefold increase of infants born
with neonatal abstinence syndrome (NAS), a withdrawal syndrome from opioids or opioid-based
medical avoidance therapy (MAT) that can cause mild to severe respiratory, central nervous
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system, and gastrointestinal distress in newborns (Haight et al., 2018; Logan et al., 2013;
McQueen, & Murphy-Oikonen, 2016; Patrick et al., 2015; Wolf et al., 2019).
Pregnancy for women with OUD presents complex medical and psychosocial issues to
manage during the pregnancy and to protect the well-being of the fetus. The common treatment
for opioid use disorder is outpatient MAT with oral administration of an authorized prescription
opioid agonist, partial opioid agonist, or opioid antagonist such as methadone or buprenorphine
(Jones et al., 2008; Keough & Fantasia, 2017; Krans & Patrick, 2016; Saia et al., 2016; Shainker
et al., 2012). Without continued treatment MAT after pregnancy, the risk of postpartum opioid
relapse is extremely high, presenting immediate health risks to the mother and infant and longterm psychosocial issues for mother, infant, family, and society (Park et al., 2012; Saia et al.,
2016).
A gap has been identified in the provision of recovery support for postpartum women
with opioid use disorder in this community in the Texas Gulf Coast region. A structured,
comprehensive interdisciplinary follow-up for mothers during the postpartum period has been
proven to reduce the risks of relapse (Forray et al., 2015). This Doctor of Nursing Practice
(DNP) nonexperimental project focused on the review of evidence-based literature, professional
guidelines, and theoretical models for the design of a comprehensive postpartum program for
women with opioid use disorder to reduce the propensity for relapse and improve the quality of
care in this population.
The needs of postpartum women with OUD are diverse and require a comprehensive
approach that is multidisciplinary in nature; therefore, the postpartum program’s design will
include the input and review of a group of expert stakeholders. This multidisciplinary group of
experts was proposed to include an obstetrician, a pediatric nurse, a social worker, an addiction
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specialist, a community health clinic advanced practice nurse who specializes in women’s health,
the director of the labor and delivery unit and nursing staff at a local hospital, a counselor from
the local Woman’s Center for Domestic Violence, and a grant writer. The addition of a grant
writer was hoped to lend credibility and feasibility to the project’s transition into practice.
Statement of the Problem
Corresponding with national trends, a community hospital in the Texas Gulf Coast region
has seen an increase in pregnant women with OUD who are being treated during pregnancy with
MAT. These women are being lost to follow up in the postpartum period, creating an increased
risk for relapse and recidivism. Although continued treatment after pregnancy is needed, the gap
in practice is that there is no formal, comprehensive program for postpartum follow-up of
women treated for OUD delivering in this facility. In order to meet a national mandate to address
the opioid crisis at the local level, a program is necessary to provide holistic care that
encompasses the complex physical, psychological, and psychosocial needs of this patient dyad.
Giving birth and assuming a maternal role can be a difficult mental and physical
transition for all women; anxiety, exhaustion, feelings of inferiority, and postpartum depression
(PPD) are common for all new mothers. The standard postpartum health issues are compounded
for women with OUD who had been treated with MAT during pregnancy, as these women are
highly susceptible to additional physical, mental, economic, and social problems; furthermore,
many of these women have experienced physical or sexual abuse, domestic violence, or
traumatic events during their lives (Baldacchino et al., 2014; Beckwith & Burke, 2015; Calhoun
et al., 2015; Humbarger et al., 2016; Kelty & Hulse, 2017; Levine & Woodward, 2018; Logan et
al., 2013; Maguire et al., 2016; McGlone & Mactier, 2015; McQueen & Murphy-Oikonen,
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2016). These historical psychosocial factors increase the risk of worsening preexisting
psychological disorders (Niccols et al., 2012).
Additionally, social disparities and biological influences create a propensity for relapse in
this population. Homelessness, unemployment, knowledge deficits related to parenting skills,
limited access to proper nutrition, lack of transportation, and absent support systems increase
feelings of helplessness in postpartum women with OUD (Niccols et al., 2012). Hormonal
changes brought on by the return to prepregnancy state can increase the physiological desire for
opioids, which may lead to the mother seeking illicit opioids to satisfy addiction cravings (Park
et al., 2012). The probability of relapse for these mothers is high; subsequently, the need for
continued formal structured care of these mothers is also high.
The development and operation of a formal, comprehensive postnatal program that
includes a plan of care for assessment and referral of women to a multidisciplinary support
system can improve the woman’s physical and mental health and increase the quality of life for
the mother-child dyad. Postpartum mothers who participate in follow-up programs for substance
abuse which incorporate psychosocial interventions aimed at improving the mother-child
relationship have shown more effective parenting skills, fewer symptoms of depression and other
physiological disorders, lower rates of possible child abuse, and a more positive report of
emotional bonding between mother and child (Niccols et al., 2012). Comprehensive formal
follow-up provides opportunities to assess adherence to medical therapy and opioid use relapse
in the mother, as well as identifying additional physical, mental, and social problems, which
require intervention.
It is important to provide a formal, comprehensive follow-up for postpartum women after
medical therapy for opioid use during pregnancy, which includes the continued assessment of the
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infant for onset or complications of NAS and developmental delay. Comprehensive care
postpartum with a transition to addiction recovery and support for mothers treated with MAT
during pregnancy and whose infants may have NAS is an important yet underresearched area.
There is a need to utilize current evidence to fill knowledge gaps and expand treatment for
postpartum women with OUD and their infants. It is believed that a multistep approach
consisting of the review of evidence-based literature, critical appraisal of evidence, and
compilation of an evidence to decision (EtD) framework to design a comprehensive formal
postnatal program may reduce the propensity for relapse and improve outcomes in this
population.
Background
Opioid Use Rates and Prevalence
Opioid use among the American population has increased at alarming rates, raising
concerns among public health officials and healthcare providers. Prescription pain relievers and
synthetic opioids are the most common drugs of choice. Opioids reduce pain and create a feeling
of euphoria that is highly addictive and can quickly lead to OUD, which is defined as “a chronic
lifelong disorder with serious potential consequences including disability, relapse, and death”
and further described as a “problematic pattern of opioid use leading to problems or distress”
(American Psychiatric Association [APA], 2018, para. 8). The disorder has become a health care
crisis that affects millions of people nationwide, necessitating the declaration of a national public
health emergency requiring urgent attention (CDC, 2019b; HHS, 2017).
In 2014, enough POPRs were legally prescribed to allow every adult in the country to
have their own bottle (Wheaton et al., 2014). Over 11 million persons reported using illicit
opioids in 2017 (Substance Abuse Center for Behavioral Health Statistics and Quality [CBHSQ],
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2018). A six-fold increase in the national rate of deaths from opioid overdose occurred from
1999 to 2017, with 400,000 opioid-associated deaths during this time (CBHSQ, 2018). Overdose
from OUD resulted in 47,600 deaths in 2017 alone: an increase of 45.2% from 2016 (CDC,
2018b). In the United States, an average of 130 opioid overdose-related deaths occur daily
(CDC, 2018b). In addition to deaths from legally prescribed and illicit opioid overdose, deaths
from methadone MAT are attributed to 33% of opioid overdose deaths (Ray et al., 2015; United
States Department of Health and Human Services, Centers for Disease Control and Prevention,
& Division of Unintentional Injury Prevention [DHHS], 2016).
Opioid Use in Women
The unique biological responses of women make them more susceptible than men to
OUD. Body composition, hormones, decreased glomerular filtration rate, and lower metabolism
rate increase the time substances take to eliminate from the female body (Legato et al., 2016).
Women are more apt to develop a substance use disorder (SUD) in response to emotions,
traumatic life events, and stress (Cheng et al., 2016; Meléndez et al., 2012; SAMHSA, 2015b).
Many women initiate substance use in response to the pressure of a relationship partner with a
substance use disorder, seeing the act as a way to bond with their partner (SAMHSA, 2015b).
Opioid misuse is often coupled with codependent tendencies, domestic violence, or other types
of abuse (SAMHSA, 2015b). Mental disorders such as anxiety and depression; history of trauma;
history of mental, physical, or sexual abuse; addictive behaviors; socioeconomic factors such as
poverty, discrimination, level of education, unemployment, and social status; and trouble with
law enforcement present risks for substance abuse and challenges with recovery for women
(SAMHSA, 2015b). Many women have issues with low self-esteem, self-worth, and self-esteem,
which lend to a predisposition to OUD (Currow et al., 2016; DHHS, 2016).
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Opioid Use in Women of Reproductive Age
Many women with a substance abuse disorder, including opioid use, are in their prime
reproductive years, defined as females age 15 to 44 (SAMHSA, 2018). The number of women of
reproductive age (WRA) affected by OUD and subsequent opioid overdose has continued to rise
at a disturbing volume. From 2008 to 2012, more than one-fourth of privately insured and close
to 40% of Medicaid-insured WRA filled at least one prescription for POPRs each year (Carter et
al., 2019; Lind et al., 2017). From 2002 to 2013, the rate of WRA reporting dependence on
heroin during the past year increased by 100% (Lind et al., 2017). From 1998 to 2011, OUD in
WRA increased by over 120% (Maeda et al., 2014). Of the 200,000 women seeking ED
treatment for OUD in 2010, over 119,500 were classified as WRA (CDC, 2018a). In 2017, over
8,000 deaths were recorded from opioid overdose in women in their reproductive years, with
over 2,900 of those related to prescription opioid pain relievers (POPRs; Scholl et al., 2019).
This trend of increasing deaths parallels reported opioid use in women of this age group, causing
major concern for their physical and psychosocial health.
Opioid Use in Pregnancy
Opioid use in pregnant women is found across all ethnic, socioeconomic, and
geographical regions. In a study across 46 states, including over 1.1 million antepartum women
with Medicaid benefits, 20% had used outpatient POPRs during pregnancy (Desai et al., 2014).
Premature deliveries, low birth weight infants, in utero passage of meconium causing respiratory
distress, and developmental growth delays are more common in infants of mothers who take
opioids during pregnancy, even with short-term or occasional use (ACOG, 2017; Park et al.,
2012). Maternal opioid use may alter neurodevelopment of the fetus and lead to autism spectrum
disorder and developmental deficits in children (Rubenstein et al., 2019). These infants are also
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at risk for other long-term cognitive, neural, and behavioral issues (Baldacchino et al., 2014;
Beckwith & Burke, 2015; Gawronski et al., 2014; Humbarger et al., 2016; Kelty & Hulse, 2017;
Levine & Woodward, 2018; Maguire et al., 2016; McGlone & Mactier, 2015; McGlone et al.,
2013; Park et al., 2012).
Treatment with MAT during pregnancy has been found to reduce addictive cravings and
curtails several health problems associated with maternal opioid use for mother and fetus during
pregnancy and at the time of delivery (Ross et al., 2015; SAMHSA, 2019a, 2019c). Abrupt
discontinuation of MAT or sudden withdrawal of opioids during pregnancy are discouraged as
these may lead to distress for both the mother and the fetus. Intermittent spikes in opioid levels
can cause physical damage to the fetus, as well as low compliance and high risk of relapse in the
mother (American Society of Addiction Medicine [ASAM], 2015; Park et al., 2012). Opioids,
including common forms of MAT, pass to the fetus during pregnancy through the maternal-fetal
circulation; however, adhering to a consistent treatment regime of MAT maintains a steady dose
to the fetus and prevents withdrawal symptoms similar to NAS in utero (ASAM, 2015; Park et
al., 2012).
Research Organization Demographics
The practice project organization is located in a county on the Texas Gulf Coast region
and is a satellite facility of a major educational hospital system in a neighboring county. The
project organization site is located in a predominantly rural county having a population of
354,195, with the city where the hospital setting is located having a population of 19,491 (Gulf
Coast Center, 2018). The county population’s mental health and substance abuse needs are
serviced by the Gulf Coast Center for Mental Health, which is located approximately 50 miles
from the project organization site (Texas Health and Human Services, 2019). There is no local
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governmental county health department program located within the immediate community. The
community does have several inpatient and outpatient substance abuse facilities, but none treat
the specific needs of postpartum women with OUD, nor do they cater to the needs of women in
general.
Though the rate of drug use in the county may be lower than some of the more populous
counties in Texas, the problem affects many in the community each year. During 2016, 58.8
opioid prescriptions per 100 persons were written for persons within the county (CDC, 2017). In
the same year, emergency medical professionals at the setting locality responded to 92 cases of
opioid overdoses, with an opioid reversal agent being administered in 12 of the cases (Gulf Coast
Center, 2018). During 2017, there were 1.08 POPR prescriptions written for each Medicaid
patient and 39 overdose deaths recorded in the county resulting in a rate of 10.8 deaths for every
100,000 persons (Foundation for AIDS Research [AMFAR], 2019). Due to being located in
close proximity to the gulf coast and the border of Mexico, the county has been identified by the
Drug Enforcement Agency (DEA) as one of 19 counties in Texas with the with the designation
of a High Intensity Drug Trafficking Area (HIDTA; Prevention Resource Center 6, 2017).
Need for the Project
There are several gaps in the provision of OUD services in this area to postpartum
women as well as the general population that fall in line with the findings of a report by the
Council on Recovery (Prevention Resource Center 6, 2017). The council found that rural
counties, especially those found along the coastal border, lacked sufficient providers to service
the population’s substance abuse needs (Prevention Resource Center 6, 2017). Because of the
low socioeconomic status of many of the residents in the area, many persons with substance
abuse issues lack financial resources, are uninsured, and do not have adequate transportation to
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travel to the Gulf Coast Center (Prevention Resource Center 6, 2017). Despite the need for
services in the county, there are no adequate resources or programs to meet the financial and
logistical needs of the residents.
The main branch of the academic hospital organization in the neighboring county has
been on the forefront of addressing the opioid crisis by implementing programs to decrease
addiction and misuse risks. Examples of programs are a physician-led initiative to decrease
overprescribing of POPRs, requiring physicians to become more accountable for the stewardship
of opioid use, continuing education programs for providers and those who administer opioids on
current guidelines, education on alternative treatments for pain such as acupuncture, pain
contracts that outline patient and provider responsibilities for pain control, and implementing
technology in the electronic health record (EHR) to access the state POPR prescribing database
before prescribing opioids (Clifford, 2018). The local facility setting for the practice problem has
benefitted from these initiatives. The organization’s culture is open to exploring new methods
and practice initiatives aimed at controlling the adverse effects of OUD on the community.
Accreditation and Certification
An opioid treatment program (OTP) is defined as a medical practice or formal program
that manages the treatment of OUD by prescribing or dispensing MAT; these programs are under
strict federal regulations requiring certification by SAMHSA, accreditation with the Joint
Commission on the Accreditation of Healthcare Organizations (JCAHO), and registration with
the Drug Enforcement Administration (DEA; SAMHSA, 2015a). The first set of guidelines,
Federal Guidelines for Opioid Treatment Programs, were published by SAMHSA in 2001 after
consensus by an expert panel convened to address the rising opioid crisis; an update to the
guidelines was published in 2007 and again in 2015 (SAMHSA, 2015a). The latest version of the
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guidelines addresses the most current trends in health care, such as technological advances
(electronic health record, telemedicine, electronic device digital therapy); drug monitoring
programs; nursing scope of practice; and a model for recovery-oriented patient-centered care
(SAMHSA, 2015a). As outlined by SAMHSA, the comprehensive guidelines can serve as a
directive to contribute to the design of a program for postpartum care for the mother-child dyad.
Since this evidence-based practice program did not include prescribing or dispensing
MAT, it was not considered an OTP under federal standards and is not held to the requirements
for certification, accreditation, or registration with the aforementioned entities. However, the
facility chosen for the setting of this practice problem meets the specification of a qualified
practice setting according to the following federal guidelines: (a) provides 24-hour emergency
services; (b) provides case management services to address behavioral health and psychosocial
follow-up needs; (c) utilizes health information technology to record in an EHR and coordinate
care; (d) is registered with the state prescription drug monitoring program (PDMP); and (e)
participates in third-party billing, private and federal insurance, and self-pay for coverage of
services (Electronic Code of Federal Regulations [e-CFR], 2020). The practice site is accredited
with JCAHO and multiple other federal and health care organizations.
Purpose of the Project
With an increase in the number of pregnant women at a community hospital in the Texas
Gulf Coast region presenting with OUD and treatment with MAT during pregnancy, a need has
been identified to reframe interventions to improve follow-up in the postpartum period to
decrease the risk for recidivism and relapse. The purpose of this scholarly Doctor of Nursing
Practice (DNP) nonexperimental prospective exploratory project was to utilize best evidencebased literature, professional guidelines, and theoretical models for the design of a

13
comprehensive postnatal program for this population. The program design uses a multistepped
Delphi technique data collection format beginning with a systematic literature review from
quantitative and qualitative evidence-based literature to format a set of formal guidelines for the
care of a vulnerable population. This program can provide a structure and process for
implementing best practice clinical guidelines for the management and support of the postpartum
mother-child dyad.
The evidence was presented to a multidisciplinary team consisting of an obstetrician, a
pediatric nurse specialist, a social worker, an addiction specialist, a community health clinic
nurse, nursing staff in the labor and delivery unit of a local hospital, and representatives from
local community agencies that offer recovery and parenting services for input into the design of a
comprehensive postnatal program. A structured multidisciplinary holistic approach to postnatal
follow-up can improve the spiritual, mental, physical, and social well-being of women with OUD
(Kerlin, 2017; SAMHSA, 2018). The project’s goal was to create a formal, comprehensive
multidisciplinary follow-up program for postnatal women who were treated with MAT during
pregnancy that will address the physical, psychosocial, and environmental needs of the motherchild dyad and improve outcomes for this population.
Significance of the Problem
Significance to Postpartum Women With OUD
Many of these women have experienced childhood and adult trauma, as well as lifelong
adversities that have played a hand in their propensity for OUD and can negatively impact
recovery and ultimately lead to relapse. During the postpartum period, the propensity for
recidivism to opioid use is increased for new mothers treated with MAT during pregnancy due to
the discontinuation of needed services. The initial physiological and psychosocial factors that
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lead to OUD still exist, combined with the stress of motherhood, feelings of guilt resulting from
social stigmas, and domestic disparities such as homelessness, poverty, and partner violence
(Cheng et al., 2016; SAMHSA, 2018; Schiff et al., 2018). A formal, comprehensive follow-up
program including treatment with MAT and the availability of essential services will help this
population navigate through the hormonal changes of the postpartum period, care of an infant
that may be unhealthy due to NAT, increased opioid cravings, psychosocial disparities, and the
risk of postpartum depression on their own (Schiff et al., 2018). The extra medical treatment,
nursing care, support, and education a follow-up program would provide could decrease the risk
for relapse for the postpartum women treated for OUD during pregnancy.
Overdose during the first year after giving birth is a major contributor to maternal
pregnancy associated death (Schiff et al., 2018). According to the Maternal Mortality and
Morbidity Task Force, in 2017, 58% of all drug-related maternal deaths in Texas that occurred
during the first year postpartum were the result of opioid overdose (Texas Department of State
Health Services, 2018). Due to the increased possibility of preexisting mental health issues
coupled with the propensity for postpartum depression in women with OUD, frequent screening
for depression, suicidal ideations, and signs of relapse should be incorporated into postpartum
care within the first year after birth (SAMHSA, 2018). Close follow up can reduce the high
overdose mortality rate for these women.
Significance to the Community
Opioid abuse has devastating effects within the community and presents a health crisis
that needs to be valiantly met with individualized programs specifically aligned to the
community resources. Early intervention is needed to nurture the development of a caring
relationship within the mother-child dyad and to build positive parenting skills that empower
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women with OUD to develop safe, stable environments in which to raise their children and reach
their full potential in the community. Many children of women with OUD become the
responsibility of the community and governmental agencies. Exposure to parental OUD during
the formative years can put children at risk for multiple health issues, learning disabilities, and an
increased propensity for future substance use disorders (Widom & Brzustowicz, 2006). This
program can help to meet the needs of communities in the overall effort to reduce opioid
dependence in the maternal population, which will help to stop the cycle of opioid misuse and
decrease the number of children placed in foster care.
Mothers struggling with OUD often do not partake in optimal self-care activities, nor do
they have the resources to take care of themselves, their responsibilities, or their children. They
can find it hard to function in daily life, with family, at work, and in the community. Often these
women face life circumstances that have been altered by loss of employment, loss of home, loss
of family support, and loss of access to the same level of medical services available during
pregnancy. These women are often unable to form meaningful personal connections and are
accustomed to living with a string of damaged relationships. Changing an addictive behavior is
challenging and becomes a lifelong effort; so many aspects of life must be changed at once,
making it difficult not to fall back into old habits (National Institute of Drug Abuse, 2017). This
population is often seen as weak; however, they can be a very resilient group of women. They
have usually overcome many obstacles and adversities within their lifetime and can be highly
motivated if given the right tools and support.
Significance to Maternal and Child Nursing
A comprehensive follow-up program for postnatal women with OUD is important to
ensure that women and children affected by this disorder receive respectful and empathetic care
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by nurses trained to recognize OUD as an addictive disease and not a social stigma. The
outcomes of a structured program for postpartum women with OUD are congruent with the
Association of Women’s Health, Obstetric and Neonatal Nurses (AWHONN) position and
standards for women with substance use disorder during pregnancy and the postpartum period. It
is AWHONN’s position to (a) not support the “incarceration or other punitive legal actions
against women” during “pregnancy and the postpartum period”; (b) screen women initially and
periodically for SUD during and after pregnancy with “a validated tool”; and (c) provide MAT
and “family focused” care that is “non-stigmatizing” (Association of Women’s Health, Obstetric
and Neonatal Nurses [AWHONN)], 2019, para. 1). Misconceptions and outdated conventions
about OUD during pregnancy and postpartum can impede the quality of nursing care.
It has not been uncommon for substance use by pregnant women and mothers of young
children to be associated with bias and prejudice, projecting shame and guilt on those who
struggle with OUD. Supportive practitioners are critical for the successful recovery and healing
of postnatal women with OUD. Following a plan of care specifically designed for postpartum
women with OUD can guide nurses in a structured format that increases their knowledge and
confidence in providing evidenced-based care for these women. A comprehensive follow-up
program managed by specially trained nurses can address opioid use recovery with a
compassionate and understanding approach that fosters a culture of support and hope and
alleviates any sense of moral failure for the mother.
Evidence-based assessment and treatment for NAS can help to decrease the morbidity
and mortality risks for the infants born to women with OUD during the postpartum period. Every
60 minutes, a child is born with NAS in the United States (Patrick et al., 2015). Infants with
NAS, or those with a risk of developing NAS, should be seen earlier and more frequently during
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the postnatal period to monitor for complications. Medical costs and resources for NAS take
away from funds and resources that could be used to treat other medical conditions. In 2016, the
cost of care for infants with NAS in Texas was over $66 million, with 74% of the costs funded
by public insurance (Myers, 2018).
Subsequent early pregnancy is a risk for women treated with MAT for OUD during
pregnancy and present with an additional set of complications for both mother and infant.
Contraceptive methods are usually discussed during the traditional six-week postpartum followup visit with the obstetrician; however, evidence has shown that only 43.8% of women with
OUD return for this visit (Parlier et al., 2014). The incidence of unintended pregnancy in women
with OUD is up to 80% higher during the first three months after delivery than that of women
without OUD (ACOG, 2017). Women are advised to abstain from sexual intercourse during the
immediate postpartum period; many women with OUD go home to an environment that makes it
difficult to abstain.
It is common for these women to engage in sexual intercourse prematurely, leading to a
subsequent pregnancy (SAMHSA, 2015b). Early conception after birth can lead to poor maternal
and neonatal outcomes. Low birth weight, preterm birth, and infant death are associated with
short interval pregnancy (Ahrens et al., 2018). The risks for maternal complications, such as
gestational diabetes and preeclampsia, increase with short interval successive pregnancy (Hanley
et al., 2017). Education on contraceptive options and usage provided during early follow-up
before the traditional six-week postpartum visit can decrease the incidence of unintended short
interval pregnancy.
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Significance to the Literature
The rates of women with OUD during pregnancy and the postpartum period are
continuing to increase, creating a need for further evidence-based literature and models of
recovery that support the specific needs of this population of women (Kerlin, 2017; SAMHSA,
2015b). There are currently several innovative programs in conception for women with OUD,
but there is a need for more programs that incorporate the complex mix of sociocultural,
environmental, spiritual, physical, and psychosocial aspects of OUD in a holistic approach that
reduces the risks of relapse and builds the self-respect of these vulnerable women. Existing
models of care and relapse prevention should be consistently evaluated for effectiveness and
modified for increased success (SAMHSA, 2017).
Nature of the Project
This was a nonexperimental multistep prospective exploratory program design project
utilizing the Delphi rounds method of expert stakeholder input for data collection. The purpose
of this scholarly DNP project was to utilize the best evidence-based literature, professional
guidelines, theoretical models, and review combined with input from an expert panel of
stakeholders for the design of a comprehensive program for postnatal women with OUD. The
project’s goal was to create a structured multidisciplinary holistic approach to postnatal followup to improve the mental, physical, and social well-being of women with OUD while decreasing
the risk of relapse and improve the quality of the mother-child dyad. The project will set the
foundation for advancing the art and science of nursing care for this population.
The project began with a systematic thematic literature review from evidence-based
practice literature and professional and government agency guidelines. A critique of the
reviewed literature was completed using the Grading of Recommendations Assessment,
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Development, and Evaluation (GRADE) system of appraisal. The GRADE Evidence to Decision
(EtD) framework was used to synthesize the evidence and form recommendations for a
comprehensive postnatal follow-up program for women with OUD who were treated with MAT
during pregnancy. The compilation of evidence and recommendations was to be presented to a
panel of interdisciplinary stakeholders at a community hospital in the Texas Gulf Coast region
that has seen an increase in pregnant women with OUD who are being treated during pregnancy
for their input and consensus.
The Delphi method is a process of gaining consensus in practice guidelines or policy
through review and communication sessions held between members of an expert stakeholder
panel (Brady, 2015). Following the Delphi method for guideline consensus, this project used a
five-step process: (a) discover evidence-based practice interventions through a systematic review
and grading of evidence; (b) formation of an expert stakeholder panel; (c) surveying the panel for
review, suggestive input, and consensus of the evidence; (d) formation of a formal set of
guidelines; and (e) a second round of review and consensus from the expert panel. This expert
opinion will be integrated into the formation of a formal program plan that includes the structure,
the evidence-based process guidelines, proposed formative and summative goals and milestones,
and a proposed budget. Theoretical models and currently operating recovery programs for
mothers at risk will be considered for guidance in formatting the guidelines. The Appraisal of
Guidelines Research and Evaluation (AGREE) II is used as a checklist by the interdisciplinary
panel to ensure the credibility of the final set of guidelines. It is hoped that this plan can be
presented to funding agencies to establish this program in the community.
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Question Guiding the Inquiry (PICOT Question)
The question guiding this program design project is as follows: Will an interprofessional
team be able to develop clinical practice guidelines for a program to follow women treated for
opioid use disorder during pregnancy with medication avoidance therapy after birth? These
guidelines could be used to construct an appropriate 12-month follow-up program to decrease the
rates of relapse and promote the maternal-child bonding process. A further description of each of
the elements of the question guiding the inquiry is as follows:
P (population): An expert panel of stakeholders that hold an interest in the outcomes of
postpartum adult women with OUD who have been treated with MAT during pregnancy and
their infants that were delivered in the same local hospital of a community on the Texas Gulf
Coast.
I (intervention and exposure): Using the Delphi mythology of guideline consensus to
perform a systematic literature review of best evidence-based literature, professional guidelines,
and theoretical models; analyzing the results of the review with the GRADE appraisal of
evidence method; transferring the findings to an EtD framework to determine best
recommendations for interventions; developing formal guidelines using the PWOUD Guideline
tool; approval of an interdisciplinary expert panel of stakeholders having an interest in the care
of women with OUD that have been treated with MAT during pregnancy. Stakeholder members
include an obstetrician, a pediatric nurse, a social worker, an addiction specialist, a community
health clinic advanced practice nurse who specializes in women’s health, the director of the labor
and delivery unit and nursing staff at a local hospital, a counselor from the local Woman’s
Center for Domestic Violence, and a grant writer.
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C (comparison or control): There is no comparison or control for this guiding question.
A comparison or control may not be relevant in a question about an outcome that is applicable to
a therapy, deeper meaning, or the prognosis of a plan (Fineout-Overholt & Johnston, 2005).
O (outcome): Result in an approved formal structured set of guidelines outlining a
comprehensive follow-up program that provides management and support for postnatal women
with OUD who have been treated with MAT during pregnancy that can improve the quality of
care and outcomes for the mother-child dyad.
T (time): The period for completing the program design project is five months.
Performing a Delphi method guideline consensus to perform a systematic literature review of
best evidence-based literature, professional guidelines, and theoretical models, and using the
GRADE method of appraisal of evidence with an EtD framework to develop a set of guidelines
based on criteria from the PWOUD Guideline checklist that has been approved by an
interdisciplinary expert panel of stakeholders will result in content consensus and approval of a
formal structured set of guidelines outlining a comprehensive follow-up program that provides
management and support for postnatal women with OUD in a community on the Texas Gulf
Coast that have been treated with MAT during pregnancy.
Theoretical Framework
The theoretical framework of the opponent process theory (OPT) can be applied to the
emotional and motivational aspects of OUD. The OPT presents that persons who are addicted to
or misuse drugs have a reduced feeling of fear that negative results will occur if they abuse
medications; instead, fear is replaced by a feeling of relief or reward (Koob, 2020). Driven by
emotions and the motivation to avoid negative side effects, the person with OUD continues to
abuse opioids in an effort to reduce withdrawal symptoms and excessive cravings (Koob, 2020).
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During the initial phases of OUD, the motivation for using opioids is to produce feelings of
enjoyment and euphoria; however, these feelings are soon replaced by negative withdrawal
symptoms when the person is unable to use additional doses of opioids. At this point, the
motivation for using opioids is driven by the need to prevent negative experiences rather than to
produce a positive experience.
During periods of withdrawal symptoms and intense cravings, the individual experiences
high levels of anxiety, as well as increased physical and emotional stress (Koob, 2020). This
cycle of stress and relief-seeking behavior leads to a lack of motivation to stop abusing opioids.
If a person does become sober, they maintain stress-induced memory that can trigger relapse
when faced with bouts of anxiety or stressful situations (Koob, 2020). It is important to provide
stress management, coping skills, and positive reinforcement to prevent the individual with OUD
from relapse. The OPT framework (see Figure 1) can be used to guide the development of a
formal structured set of guidelines outlining a comprehensive follow-up program that provides
management and support for postnatal women with OUD and prevent them from relapse and
recidivism.
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Figure 1
Theoretical Framework for Opponent Process Theory
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Operational Definitions
Buprenorphine. A medication therapy for opioid use that mimics the effects of opioid
medications without creating increased cravings; this medication can be self-administered with
an authorized prescription (SAMHSA, 2019a).
Medication avoidance therapy. A type of therapy for OUD that includes the use of
medications such as methadone and buprenorphine to assist with the withdrawal from opioids
and the management of cravings; this type of therapy is usually prescribed in conjunction with
counseling (Koehl et al., 2019).
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Methadone. A synthetic medication treatment used to treat OUD by blocking the effects
of opioids, thus reducing cravings and withdrawal symptoms; this medication must be
administered through a highly regulated physician clinical setting (SAMHSA, 2019c).
Mother-child dyad. The coupling of the mother and the child into a single patient care
unit based on the dependent relationship of the mother to the child and the child to the mother
(Romanowicz et al., 2019).
Neonatal abstinence syndrome (NAS). A disorder that can present in infants of mothers
with OUD derived from in utero exposure to opioids or medication treatment for OUD causing
severe gastrointestinal and neurological symptoms; NAS generally necessitates intensive medical
care for the infant and can result in permanent health issues (Kocherlakota, 2014).
Opioid use disorder (OUD). A repeated pattern of behavior characterized as a strong
craving for opioids and a loss of control over the number of opioids taken, leading to social
problems, risky behaviors, increased tolerance, and withdrawal when opioids are not taken
(APA, 2018).
Opioids. A medication that reduces pain and creates a sensation of euphoria by binding
to the stimulating reward pathways in the brain and spinal cord; opioids consist of legal
prescription medications such as oxycodone, hydrocodone, fentanyl, and morphine, and illegal
drugs such as heroin (Hawk et al., 2015).
Scope and Limitations
The structured follow-up program for pregnant women with OUD who were treated with
MAT during pregnancy will help guide the health care team providing long-term recovery care
to a set of women delivering at a local teaching hospital. The hospital is a smaller branch of a
major medical and nursing teaching hospital on the Texas Gulf Coast; the local setting is one of
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three community hospitals in the south region of the county and is the primary facility providing
care to the underserved and indigent population. The hospital offered a combination of MAT and
perinatal care through a community clinic up until July of 2019, at which time the obstetrician in
practice at the clinic met with an untimely death. The hospital has continued to provide delivery
service to this specialized population of women; however, treatment with MAT was not
continued through the hospital. The patients of this particular clinic were divided between
physicians from the main campus of the hospital organization.
Members of the health care team will include nurses in the labor and delivery unit who
provide immediate postpartum care and discharge for the designated patient population, nurses
within the community health department, the hospital’s women and children’s clinic, obstetrician
and pediatrician’s office, addiction specialists, and other involved members of involved social
and community services. Consultation and input during the program design were sought from
individuals and organizations that have contributed to the design and development of similar
projects in other communities. The project covers the review and synopsis of peer-reviewed
literature written from 2014 to 2019, current addiction and women’s health professional
organization guidelines, and currently in-service evidence-based practice models. A review of
the evidence was presented for further evaluation and critique by an expert committee to direct
the writing of a set of guidelines for a structured follow-up program. The committee met in the
conference room provided by the designated community hospital and through virtual
conferencing due to COVID-19 restrictions.
The actual final program was not implemented within the context of this DNP project but
will serve as the groundwork for a pilot program within the hospital and a grant proposal to
commence a formal program within the community. Prospective committee members were
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excluded from participation in the health care team if they do not currently provide care in the
labor and delivery unit of the designated hospital, do not practice in the obstetrics, pediatric, or
addiction health care fields, or do not participate in the provision of social or community services
in the coverage area of the designated hospital facility.
Constraints related to the health care aspect of the project include (a) a small community
setting with a limited population of health care, social, and community services professionals to
solicit as committee members; (b) a nursing staff at the hospital that is not experienced with the
integration of care for opioid use into their normal delivery and discharge practice; and (c) the
recent death of the primary physician providing both obstetrical care and MAT as a combined
practice for the targeted population. Active recruitment for an alternative physician is in
progress. The busy schedules of the other professionals on the health care review team may
interfere with maintaining a consistent participation agenda throughout the review process. A
plan to provide access to Delphi rounds via online format will be considered during project
implementation. The funds for the projected budget, including compensation for professionals to
attend meetings, may be more than is available to the DNP student; however, an online format
may reduce the cost of project implementation.
Chapter Summary
The incidence of OUD across the nation is an increasing problem. Especially troubling is
the rising rate of women presenting with OUD during pregnancy. The standard treatment for
OUD during pregnancy is MAT with methadone or buprenorphine, which curb cravings for the
mother and reduce life-threatening withdrawal symptoms for both the mother and fetus. As with
opioid use, MAT leads to the risk of a NAS for the infant; NAS is a dangerous complication that
can result in intensive care, life-long physical and neurological damage, or death for the infant.
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Postnatal care of the mother should include the continuation of MAT to reduce the risk of relapse
to the use of illicit opioids. In a small community on the Texas Gulf Coast, there has been found
to be a gap in the transition of care during the postnatal period for women with OUD who were
treated with MAT during pregnancy. There is no formal, comprehensive program to follow up
with the mother-child dyad to monitor the infant for NAS, continue MAT for the mother, or
address the many psychosocial disparities often present.
The purpose of this DNP Delphi method nonexperimental project using an integrative
thematic literature review was to compile best practice evidence from scholarly sources and
professional and government organizations into an EtD framework to be appraised by an expert
panel and used to create a guideline for a formal, comprehensive multidisciplinary follow-up
program for postnatal women who were treated with MAT for OUD during pregnancy. This
nonexperimental program design project will help to guide nursing professionals in the care of
postnatal women with OUD and improve the quality of the mother-child dyad.
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Chapter 2: Literature Review
Corresponding with national trends, a community hospital in the Texas Gulf Coast region
has seen an increase in pregnant women with OUD who are being treated during pregnancy with
medical avoidance therapy. These women are being lost to follow up in the postpartum period,
creating an increased risk for relapse and recidivism. Although continued treatment after
pregnancy is needed, the gap in practice is that there is no formal program for postpartum
follow-up of women treated for OUD who have delivered in this facility. The purpose of this
DNP project is to design a set of program guidelines for a comprehensive postnatal follow-up
program for women with OUD who were treated with MAT during pregnancy.
The research question addressed in the project was, Will an interprofessional team be
able to develop clinical practice guidelines for a program to follow women treated for opioid use
disorder during pregnancy with medication avoidance therapy after birth? These guidelines could
be used to construct an appropriate 12-month follow-up program to decrease the rates of relapse
and promote the maternal-child bonding process.
This project was a clinical practice guideline design format consisting of a systematic
review of best practice evidence-based literature, appraisal of the evidence, transferring the
evidence to recommendations, presenting the recommendations to an expert panel of interdisciplinary stakeholders for critique, developing a set of formal guidelines, and final
presentation of the guidelines for critique and approval from the stakeholders. This chapter
describes the evidence-based practice search methodology to identify relevant concepts to further
understand opioid use in pregnant and postnatal women and the particular needs of this
population. Gaps in knowledge are identified based on what is known from current literature.
Furthermore, fundamental and conceptual theory to guide the practice design project isdiscussed.
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Search
To present a comprehensive overview of opioid use in pregnant and postpartum women
and the specific needs of the mother-infant patient dyad, a literature review was conducted to
explore the concepts surrounding this practice problem. This review contained an analysis of
qualitative and quantitative studies that contributed to what is known about the various aspects of
OUD in pregnant and postpartum women and the issues contributing to the propensity for
relapse. An Internet search was conducted for relevant literature from the nursing databases at
the Margaret and Herman Brown Library at Abilene Christian University (ACU), which is
comprised of the following databases: CINAHL, Health Source: Nursing/Academic, and
MEDLINE. Other databases provided through the same library resource were also searched, such
as Academic Search Complete, Alternative Health Watch, ProQuest Nursing and Allied Health
Database, PubMed, Science Direct, Social Work Abstracts, and SAGE Research Methods.
In addition to the ACU library, additional Internet searches provided background and
general knowledge to support the primary problem. The results of the Internet searches included
the Cochrane database and various professional and government organizations, including the
American College of Obstetricians and Gynecologists; American Psychiatric Association;
American Society of Addiction Medicine; Association of Women’s Health, Obstetric and
Neonatal Nurses; Centers for Disease Control and Prevention; National Academies of Sciences,
Engineering, and Medicine; National Committee for Quality Assurance; National Institute of
Drug Abuse; Substance Abuse Center for Behavioral Health Statistics and Quality; Substance
Abuse and Mental Health Services Administration; Texas Department of State Health Services;
and the United States Department of Health and Human Services. The professional and
government organizations provided statistical information and guidelines for care of women with
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substance use disorders and their children. Over 300 full-text peer-reviewed English-only articles
published between 2012 and 2019 were reviewed; 23 were selected to contribute to the content
of this DNP project.
Theoretical Framework
Addiction theory appropriately explains the physical and psychological aspects of
substance abuse, including OUD. Several addiction theories can be applied to the exploration
and explanation of addiction, leading to a better understanding when planning care for the
postpartum woman with OUD. After reviewing various theories, the opponent process theory
(OPT) was chosen to explain the emotional and motivational struggle with addiction and relapse
that this population faces as they navigate through the fourth trimester. There has been much
debate in the neuroscience and psychological disciplines to determine if OUD and addiction in
general, is a pathological disorder of the brain or a psychological illness (Farisco et al., 2018).
What is known is that “addiction can be described as a chronically relapsing brain disorder
which shares the same brain pathways of reward systems” (Farisco et al., 2018, p. 1).
The premise of OPT is based on the cycle of transforming fear from negative
consequences of opioid use to the satisfaction felt by the reward system that is achieved when
opioids are used in the presence of stressful situations (Koob, 2020). Koob (2020) stated,
“Negative emotional states set up a powerful motivational state for relapse” (p. 45). Compulsive
reactions caused by emotions evoked from stressful situations lead to relapse to opioid use,
driven by decreased self-control, impaired reasoning, and the inability to effectively make
decisions (Farisco et al., 2018). Stress increases cravings for reward satisfaction and relief,
feeding the cycle of addiction and decreasing the fear of negative consequences (Farisco et al.,
2018; Koob, 2020).
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When applying OPT to the postpartum women with OUD during the fourth trimester, the
various psychosocial dynamics associated with new motherhood, caring for a child with NAS,
and attempting to maintain sobriety in a high-stakes environment provide stressful situations that
lead to emotional distress, compulsive cravings, and tendency to find relief through opioid use.
Although the postpartum woman with OUD who was treated with MAT during pregnancy may
be motivated to refrain from the negative effects of drug use on herself and unborn child,
stressful situations may trigger a need for relief and a positive experience (Koob, 2020).
Developing a program for this population that addresses the need to reduce disparities and
stressful environmental stimuli can positively influence the cycle of transforming fear to reward
and reducing the tendency to relapse.
Review of Literature
Treatment of OUD in Pregnancy
Methadone and buprenorphine are medications that are commonly used to treat OUD and
manage withdrawal symptoms. Methadone, a mu-opioid receptor agonist that alters the
interpretation of pain, has been widely prescribed to decrease withdrawal symptoms and cravings
during recovery from opioid misuse, although some addictive feelings of euphoria usually
remain until the patient becomes resistant to the effects (APA, 2018; ASAM, 2015; Ross et al.,
2015; SAMHSA, 2019c). Buprenorphine is an opioid derivative with mixed agonist-antagonist
effects also used for opioid dependency and to manage withdrawal symptoms (ASAM, 2015).
Methadone is provided in pill form for daily dispensation at highly regulated clinics due to strict
monitoring requirements; buprenorphine is prescribed weekly in pill form and can be filled at a
pharmacy (APA, 2018; ASAM, 2015). Both medications are approved for the treatment of OUD
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in pregnancy; however, buprenorphine has been found to have fewer side effects for the mother
and infant (Carter et al., 2019).
It is recommended that women continue with a consistently monitored MAT regime
throughout the entirety of the pregnancy to maintain uniform drug levels in maternal and fetal
circulation, decrease opioid cravings in the mother, and decrease adverse health outcomes in the
fetus (Baldacchino et al., 2014; Kelty & Hulse, 2017; Levine & Woodward, 2018; Park et al.,
2012). Withdrawal symptoms of opioid or MAT can begin as soon as six to 12 hours after the
last opioid dose, causing extreme sympathetic nervous system stimulation in the mother and
fetus (ASAM, 2015; Denenberg & Curtiss, 2016). The health risks to the fetus associated with
opioid use during maternal relapse outweigh the potential health risks to the fetus from
methadone or buprenorphine therapy (ASAM, 2015).
During the third trimester of pregnancy, the increased blood circulation and metabolism
of the maternal body lead to lower levels of methadone in plasma and increased MAT clearance
times (ASAM, 2015). Dosage levels are generally increased until after delivery to maintain
therapeutic levels. Postpartum MAT must be continued, adjusting medication and dosage as
needed to reflect the retrogressively changing metabolism of the mother (ASAM, 2015; Park et
al., 2012).
Neonatal Abstinence Syndrome (NAS)
In addition to the negative impact OUD has on the physical health of the mother,
maternal opioid use before, during, and after pregnancy can cause devastating health outcomes
for the fetus. During the withdrawal period, infants with NAS can display a myriad of symptoms,
which may include extreme and spontaneous high-pitch crying, tremors, hyperactive reflexes,
and an inability to sleep (Haight et al., 2018; Logan et al., 2013; McQueen & Murphy-Oikonen,
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2016; Patrick et al., 2015; Wolf et al., 2019). Additional symptoms include decreased desire to
feed, poor sucking reflex, skin mottling, extreme movements, convulsions, fever, excessive
yawning, difficulty breathing, increased respirations and heart rate, vomiting, and diarrhea
(Haight et al., 2018; Logan et al., 2013; McQueen & Murphy-Oikonen, 2016; Patrick et al.,
2015; Wolf et al., 2019). A higher rate of infants born with gastroschisis, a disorder characterized
by contents of the abdomen protruding outside of the abdominal wall at birth, has been
associated with counties that had higher POPR use in WRA (CDC, 2020; Short et al., 2019).
Neonatal abstinence syndrome symptoms occur in up to 95% of infants born to women who take
opioids or are treated with MAT during pregnancy, with up to 50% of cases necessitating
prolonged medical treatment, including admission to the neonatal intensive care unit (NICU;
Baldacchino et al., 2014; Gawronski et al., 2014; Kelty & Hulse, 2017; Maguire et al., 2016).
This results in separation of the mother and infant during the important postnatal bonding period
and psychological distress for mothers observing infant suffering (Park et al., 2012).
Manifestations of NAS can present with a wide range of symptoms that frequently occur
within the first 72 hours after birth, lasting anywhere from a few days to several weeks.
However, the infant may not show signs and symptoms for up to two weeks after birth (ACOG,
2017; Logan et al., 2013). Treatment for NAS increases the use of health care resources and
financial costs associated with newborn care, which consists of strict monitoring and
management of symptoms by medical staff, most always requiring admission to the NICU
(Logan et al., 2013). Infants exposed to opioids in utero should be assessed for symptoms, or
complications, of NAS for an extended two-week period following discharge from the delivering
facility. Mothers who have returned to opioid use may not have the essential knowledge to
recognize complications in the newborn or new-onset NAS.
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Unique Needs of Postnatal Women
Traditionally, the postpartum care period has been defined as the hour after birth through
the first six to eight weeks after delivery. The emerging consensus is postpartum care should
continue to include the first year after birth, with reference to this longer postpartum period as
the fourth trimester (ACOG, 2018). Comprehensive care during the fourth trimester should
address the physical and psychological changes the woman experiences during this time and
should include emotional, sexual, and physical recovery; management of health and chronic
disease; contraception and family planning; and screening for depression, mood disorders, sleep
disturbances, and issues caring for the infant (ACOG, 2018, Haran et al., 2014; Suplee et al.,
2014; Thiel de Bocanegra et al., 2013).
Women and men differ in the progression to OUD both physiologically and
psychologically. More women than men use prescription opioids to ease chronic pain for longer
timeframes, in stronger doses, and more frequent episodes (Bawor et al., 2015). The rate of OUD
from prescription opioids is subsequently higher in women than in men; furthermore, the burdens
created by the disorder are felt more strongly in women (Bawor et al., 2015). Women experience
more health issues and psychosocial problems related to opioid use than do men (Bawor et al.,
2015). Gender-specific treatments are needed to address the increased physical, psychological,
and social implications of OUD in women (Bawor et al., 2015). Barbosa-Leiker et al. (2018)
found that more women than men had been previously treated for OUD, entered treatment for
OUD earlier, reported using opioids for fewer years, were less likely to actively participate in
treatment, and had lower retention. Additionally, more women than men with OUD had been
victims of sexual or physical abuse and reported previous suicide attempts (Barbosa-Leiker et al.,
2018).
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Role Transition Anxiety
Anxiety accompanying the transition associated with becoming a new mother can be
overwhelming for any woman but is especially troubling for postnatal women with OUD. During
pregnancy and the postnatal period, women with OUD have a propensity for anxiety and other
mental health disorders, with over 64% of women in this population found to have one or more
disorders according to a recent study; 40% were evaluated to have anxiety, 32% were diagnosed
with depression, and over 12% admitted to thoughts of suicide within the past 30 days from
evaluation (Benningfield et al., 2010). Anxiety and other psychological disorders such as
depression highly contribute to a propensity for relapse (Khazaee-Pool et al., 2019).
Postnatal women with OUD have a propensity for low self-esteem, ineffective coping,
and may experience a sense of loss of control over their circumstances, which can lead to
increased anxiety (SAMHSA, 2015b). Low self-efficacy usually accompanies OUD, which can
lead to poor nutrition, health problems, altered sleep cycles, and severe depression (Currow et
al., 2016). Women with OUD during pregnancy and the postnatal period usually internalize guilt
and shame related to the negative social stigma associated with substance abuse, especially since
they are also responsible for the consequences their drug use has on the fetus or newborn
(DiReda & Gonsalvez, 2016).
Lack of Follow-Up Care
Up to 40% of women in the general population do not return for a postpartum follow-up
appointment (ACOG, 2018). In 2017, 64.4% of women on Medicaid returned for a postpartum
follow-up visit within 56 days from delivery; between 67.5% and 74.9% of women with
commercial insurance returned for a visit (National Committee for Quality Assurance [NCQA],
n.d.). The lack of early postnatal follow-up can result in several physical and psychosocial
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problems for the women with OUD, missed opportunity for resources, and lead to relapse
(Beckwith & Burke, 2015; Kocherlakota, 2014; Maguire et al., 2016).
The postpartum follow-up appointment customarily includes discussion regarding family
planning and contraception, which can decrease the chance of unplanned pregnancy, a high-risk
for this population (Thiel de Bocanegra et al., 2013). Although women are advised to abstain
from sexual intercourse during the immediate postpartum period, many women with OUD go
home to an environment that makes it difficult to withstand. It is common for these women to
engage in sexual intercourse prematurely, leading to a subsequent early pregnancy (SAMHSA,
2015b).
Barriers to returning for follow-up in these women often include no childcare for the
newborn or other children, fear of the possible loss of custody of children, fear of the reaction of
the significant other (especially relevant if domestic violence exists within the relationship),
inability to cope with anxiety and stress, lack of transportation, and lack of finances (SAMHSA,
2015b). Many women with substance disorders have developed negative connections with the
medical and social professions that has led to distrust in providers, making it difficult for them to
adhere to follow-up or reach out to meet sudden needs (Beckwith & Burke, 2015; Levine &
Woodward, 2018; Maguire et al., 2016).
Lack of Support for Sobriety
Significant partners are oftentimes not supportive of the sobriety efforts of postnatal
women with OUD. Many partners, family members, and acquaintances of the women are
continuing to participate in negative lifestyle behaviors such as engaging in substance use,
tobacco and alcohol use, and involvement in risky sexual behaviors (Krans et al., 2015). These

37
women are frequently victims of sexual and physical violence inflicted by their partners as
persuasive techniques or punishment for refusing to engage in substance use (Krans et al., 2015).
Khazaee-Pool et al. (2019) found that five common causes of relapse in women with
OUD were physical withdrawal complications, psychological distress of abstaining, family
dynamics, socioeconomic factors, and cultural disparities. Studies have found that up to 63% of
women with OUD lived with a person who also had a substance abuse problem, increasing the
chance of relapse in these women (Dolan et al., 2012; Khazaee-Pool et al., 2019). Partners and
family members have been known to express disappointment and anger toward attempts of the
women to seek OUD treatment causing fear of retribution and abandonment (Khazaee-Pool et
al., 2019).
Search Limitations
Although the amount of research has increased in response to the rising opioid abuse
epidemic in the United States, interventions to understand how to treat this population have not
increased with the same momentum (Brecht & Herbeck, 2014; Janisse et al., 2014; Tzilos et al.,
2013). Specific research on OUD in pregnancy and postpartum, the care of the mother-child
dyad, the care of infants with NAS, and the development of programs and pregnant and
postpartum women with OUD make up a vulnerable population needing an increased focus on
planning care to meet the many challenges faced on a daily basis.
More research is needed across all aspects of this patient dyad, including methods to
deter and decrease the propensity for relapse in postpartum women; address the many
psychological issues and sociological disparities that face new mothers with OUD; educating
mothers on the signs, symptoms, treatment, and care of infants with NAS; the unique parenting
needs of women during the fourth trimester; collaboration of health and community services to
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provide one-stop care; and education to prepare nurses care for the patient dyad influenced by
OUD.
Chapter Summary
This chapter documented the findings of a literature review and was conducted to
describe variables related to the delivery of care to the postpartum women with OUD who were
treated with MAT during pregnancy. Findings indicated that the standard treatment of OUD
during pregnancy is MAT with methadone or buprenorphine, medications that decrease the
cravings and withdrawal symptoms associated with abstinence of opioid use. Infants of mothers
with OUD are susceptible to developing NAS, which exposes the infant to physical
complications requiring a higher level of care. Mothers with OUD must be responsible for the
increased level of care once the infant is discharged from the hospital setting. Women have a
unique set of physical and psychosocial risks for and response to OUD than do men; this set of
risks should be considered when planning care for women with OUD. A lack of a supportive
environment during the year after delivery results in an increased propensity for relapse for these
women.
Addiction theory can provide an understanding of the process of OUD and guide the
understanding of the development of a comprehensive program for postpartum women with
OUD. Koobs’ (2020) theory of opponent process explains the transition of fear of consequences
of opioid use to an overriding desire to provide relief from stressful situations. This drive to find
a release leads women to attempt to overcome the difficulties associated with the fourth
trimester, creating a propensity for relapse.
The following chapter will describe the methodology of this DNP project, which is a
nonexperimental program design project to improve the mental, physical, and social well-being
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of women with OUD while decreasing the risk of relapse and improve the quality of the motherchild dyad. The project included a systematic thematic literature review from evidence-based
practice literature and professional and government agency guidelines; use of the Grading of
Recommendations Assessment, Development, and Evaluation (GRADE) system of appraisal and
the GRADE Evidence to Decision (EtD) framework to synthesize the evidence and form
recommendations for a comprehensive postnatal follow-up program for women with OUD who
were treated with MAT during pregnancy. The compilation of evidence and recommendations
was presented to a panel of interdisciplinary stakeholders at a community hospital in the Texas
Gulf Coast region that has seen an increase in pregnant women with OUD who are being treated
during pregnancy for their input and consensus.

40
Chapter 3: Methodology
Corresponding with the rising rate of opioid use across the nation, the number of
pregnant women with OUD is increasing at alarming rates (Brogly et al., 2018; Haight et al.,
2018). Current best practice for these women is to follow a treatment plan that incorporates MAT
during pregnancy to maintain a steady dose of opioids in the maternal-fetal bloodstream and
avoid dangerous withdrawal symptoms in the mother and fetus (ASAM, 2015; Park et al., 2012).
At a community hospital in the Texas Gulf Coast region, a gap in practice has been found to
which there is no formal structured follow-up for postnatal women who have been treated with
MAT for OUD during pregnancy. This gap in practice leaves this population of women at high
risk for relapse to opioid use during a period that is characterized by numerous physical, social,
and psychological complexities (Baldacchino et al., 2014; Schiff et al., 2018).
This DNP clinical guideline development process used best evidence literature,
professional standards, existing program models, and expert input from an interdisciplinary panel
of stakeholders to create a set of guidelines for a formal, comprehensive postnatal follow-up
program for women who have been treated with MAT for OUD during pregnancy. The goal of
the clinical guideline development project was to develop a set of clinical guidelines
recommended by an expert panel; these guidelines will lead to enhanced nursing care for the
postpartum women and improve outcomes for the mother-child dyad.
This chapter presents a further explanation of the design of the DNP nonexperimental
project to include an explanation of the objectives and steps to be taken, the appropriateness of
the chosen methodology, the role of the interdisciplinary team to promote interprofessional
collaboration, a description of the practice setting, feasibility of the timeline for the project,
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projected budget for executing the project, and the institutional review board (IRB) process for
the chosen facility and Abilene Christian University (ACU).
Purpose
In response to an increase in the number of pregnant women at a community hospital in
the Texas Gulf Coast region that have been treated with MAT during pregnancy for OUD, a need
has been identified to develop a set of clinical guidelines to improve follow up during the first
year after birth, also referred to as the fourth trimester. In an effort to decrease the risk for relapse
in these mothers and to improve the care of the mother-child dyad, this scholarly DNP
nonexperimental project systematically reviewed best evidence-based literature, professional
guidelines, and theoretical models to create a set of guideline recommendations for a
comprehensive postnatal program for this population to be presented to an expert panel of
stakeholders for review.
Project Design
This DNP project used a clinical practice guideline design using the Delphi methodology
through a multistage approach based on the application of the findings from a systematic
thematic review of evidence, grading of evidence, and input from an interdisciplinary expert
panel of stakeholders associated with the local community of the practice setting. The Delphi
method focuses on guideline development through expert panel input with the goal of group
consensus. Evidence-based recommendations and expert input were used to develop a formal,
comprehensive set of guidelines and presented to the interdisciplinary panel for acceptance.
Four main objectives were set out. The first and fifth objectives each included two steps.
The program design project was to be completed as follows:
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I.

Objective one: To prepare a thorough review and critique of evidence-based
literature.
a. Step one: Conduct a systematic thematic literature review from evidencebased practice literature and professional and government guidelines for the
management of OUD during the postnatal period.
b. Step two: Compile a critique of the reviewed literature using the Grading of
Recommendations Assessment, Development, and Evaluation (GRADE)
system of appraisal.

II.

Objective two: To synthesize the evidence using the GRADE Evidence to Decision
(EtD) framework to form recommendations for a comprehensive postnatal follow-up
program for women with OUD who were treated with MAT during pregnancy.

III.

Objective three: To present a draft of the compilation of evidence and
recommendations to a panel of interdisciplinary stakeholders at a community hospital
in the Texas Gulf Coast region that has seen an increase in pregnant women with
OUD who are being treated during pregnancy for input and consensus of expert
opinion. This objective will be met using the Delphi method of gaining consensus of
group opinion on recommendations for final guideline development. Qualitative data
will be collected during this phase of the project.

IV.

Objective four: To formalize and develop a final report of guidelines based on expert
panel input and opinion that includes the structure, the evidence-based process
guidelines, proposed formative and summative goals and milestones, and a proposed
budget.
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V.

Objective five: To gain approval of the final compilation of evidence and
recommendations after modification from a panel of the initial interdisciplinary
stakeholders at a community hospital in the Texas Gulf Coast region.
a. Step one: Present the finalized program guidelines of the comprehensive
postnatal follow-up program for women with OUD who were treated with
MAT during pregnancy to the initial panel of interdisciplinary stakeholders at
a community hospital in the Texas Gulf Coast region that has seen an increase
in pregnant women with OUD who are being treated during pregnancy.
b. Step two: Use the International Appraisal of Guidelines Research and
Evaluation (AGREE) II criteria as a checklist for the interprofessional review
of the finalized formal, comprehensive guideline design.
c. Step three: Qualitative data will be collected during this phase of the project
and measured using a quantitative Likert scale.

Methodology Appropriateness
Literature Review With GRADE System of Appraisal
The first phase of the project commenced with a qualitative systematic thematic literature
review from evidence-based practice literature and professional and government guidelines for
the management of OUD during the postnatal period. The systematic research design allows the
DNP student to gain insight into the information found during the systematic review as it applies
to the particular circumstances and socioeconomic culture of postnatal women OUD (Polit &
Beck, 2017). A systematic review of literature is a synthesis of evidence-based sources, with the
purpose being to form an unbiased, comprehensive appraisal of all relevant evidence pertinent to
a research question (Aromataris & Pearson, 2014). Systematic reviews stem from evidence found
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in peer-reviewed current and historic literature and are often used to determine specific questions
related to health care decisions and the design of guidelines (Aromataris & Pearson, 2014).
Systematic reviews seek to answer a defined research question while reducing the risk of
bias during the process. Using the developed patient and population, intervention, comparison,
outcome, and timeframe (PICOT) question for the program design project, a thorough search of
available studies and guidelines started with the postnatal care of women with OUD who were
treated with MAT during pregnancy. The Abilene Christian University library collection of
databases, Campbell Database of Systematic Reviews, Cochrane Collaboration, and relevant
professional and government agency websites were searched for qualitative and quantitative
literature that met the designated inclusion and exclusion criteria.
Inclusion criteria included the care of pregnant women with opioid use disorder, postnatal
care of women with opioid use disorder medication avoidance therapy for opioid use disorder
during pregnancy, recovery models for women with opioid use disorder, neonatal abstinence
syndrome, care of the infant with neonatal abstinence syndrome, and interdisciplinary care of
pregnant women with opioid use disorder. Additional terms were included to field for outliers:
peripartum, postpartum, pregnancy, opioid abuse, opioid addiction, substance abuse, and
substance use. Exclusion criteria included women who are not perinatal or postnatal, incarcerated
women, and women with addictions to multiple substances.
The GRADE method of appraisal was designed by the GRADE working group to critique
bodies of evidence to help determine the strength of the recommended interventions for clinical
practice. The GRADE system is currently used by over 100 reputable research organizations
across the world, including the Cochrane Collaboration, the World Health Organization (WHO),
and the National Institute for Health and Care Excellence (NICE; Alonso-Coello et al., 2016).
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The GRADE method has three significant factors that make it different from other methods of
literature review appraisal. These factors include (a) the quality of evidence is separated from the
strength of recommendations, (b) the quality of evidence for each designated outcome is assessed
separately, and (c) certain criteria determines the possibility for observational studies to be
upgraded in reference to the quality of evidence (Goldet & Howick, 2013). The development of
GRADE included consideration of the versatility of the method used across the scope of health
care settings; therefore, the method can aptly be applied to community health care clinical
practice questions (Dijkers, 2013).
The GRADE system is a five-step process where evidence is initially rated as high for
randomized controlled studies or low for observational studies in step one. In step two, the initial
ranking is either upgraded or downgraded (Goldet & Howick, 2013). Evidence can be upgraded
for large consistent effect, dose response is proportionate to exposure, or actual effect is larger
than suggested when confounders are removed and downgraded for risk of bias, inconsistency,
indirectness, imprecision, or publication bias (Goldet & Howick, 2013). Step three assigns a final
grade to the evidence of high, moderate, low, or very low, designating varying degrees of
confidence in the end effect of evidence-based interventions in relation to the estimated effect of
the intervention (Goldet & Howick, 2013). Step four considers other factors that may affect the
appropriateness of recommending the intervention. These factors include the balance of desirable
and undesirable effects, cost-effectiveness of the intervention, and the preferences of the targeted
patient population (Goldet & Howick, 2013). The fifth and final step is to recommend using the
intervention in terms of direction and strength: direction of recommendation as for/against and
strength as strong/weak (Dijkers, 2013).
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GRADE EtD Framework
Building on the GRADE method of appraising the strength of evidence, the GRADE
working group developed the GRADE EtD framework to facilitate the process of transferring
evidence practice. Alonso-Coello et al. (2016) stated the rationale of the GRADE EtD
framework is to guide panels to “use evidence in a structured and transparent way to informs
decisions in the context of clinical recommendations, coverage decisions, and health system or
public health recommendations and decisions” (p. 361). The EtD framework allows for the
adaptation of decisions and recommendations to fit the dynamics of the population to be
affected, explains the pros and cons of the evidence, summarizes the evidence incorporating
relevant criteria for decision-making, allows panels to follow a “structured and transparent”
format for discussion, allows users of the final recommendations to identify supporting evidence
for justification of panel decisions, and assists users to determine if recommendations should be
adopted in their particular practice setting (Alonso-Coello et al., 2016, p. 361). The framework is
comprised of three steps: (a) formulating a PICOT question, (b) making an assessment of the
evidence, and (c) forming conclusions from assessments and judgments of evidence (AlonsoCoello et al., 2016).
Development of the Final Report of Guidelines
The role of the DNP nurse often calls for the translation of evidence into the development
of guidelines that serve as practice-change protocols to increase the quality of care and improve
outcomes “by reducing healthcare variations, improving diagnostic accuracy, promoting
effective therapy, and discouraging ineffective – or potentially harmful – interventions”
(Rosenfeld et al., 2013, p. S3). Used to translate best evidence into practice protocols, guidelines
build a framework for which to “make better decisions, initiate quality improvement efforts, and
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prioritize new research initiatives, and support coverage or reimbursement for appropriate
services (Rosenfeld et al., 2013, p. S4). Clinical guidelines must be founded on strong best
evidence, on certainty, not clinical judgment or previous nursing experience (White et al., 2016).
Best evidence has been rigorously scrutinized by interdisciplinary teams and has been found to
“direct a particular action” and can be “disseminated for use by many other professionals in the
form of practice guidelines” (White et al., 2016, p. 168).
Local practice settings may develop clinical guidelines specific to the needs of the
organization, community, and targeted patient population and adapt national or state guidelines
to ensure applicability and feasibility within the practice setting (White et al., 2016). National
and state guidelines may not efficiently address all aspects of a practice problem that is rapidly
increasing in severity, such as the lack of follow up for postnatal women with OUD;
interprofessional teams must work together “across all phases of the work of practice guideline
development, implementation, and evaluation (Prior et al. as cited in White et al., 2016, p. 168).
As new best evidence is added to professional resources and databases, it must be
integrated into practice in an efficient and timely manner, taking into consideration the evidence
may be several months, or years, old by the time it is published (National Academies of
Sciences, Engineering, and Medicine [NASEM], 2018). The methodology of this
nonexperimental program design project includes an interdisciplinary team to critique, make
recommendations, and apply the PWOUD Guideline criteria as a checklist to determine the
credibility of the guideline design process. The guidelines will be based on the findings from the
systematic literature review, GRADE system of appraisal, GRADE EtD framework, and input
from the interdisciplinary expert panel. Theoretical models and literature from current recovery
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programs for mothers with OUD will be reviewed and considered for examples when formatting
guidelines and supplemental materials.
AGREE II Checklist
The AGREE II checklist tool is an internationally used method of monitoring quality and
transparency during the development of clinical practice guidelines; the tool is also used to
evaluate guidelines for credibility (Brouwers et al., 2016). The original version of the tool
consisted of 23 items with definitions and detailed criteria related to quality and transparency of
recommendations within guidelines; the tool was internationally tested for validity (Brouwers et
al., 2016). The AGREE II tool was later developed from recommendations from several users
and developers who had previously used the tool. The AGREE II tool has been adapted to create
the new Postnatal women with opioid use disorder (PWOUD) tool used as a checklist the DNP
can utilize to guide the development and assess the quality of clinical practice guidelines. The
PWOUD checklist was used during the Delphi rounds presented to the interdisciplinary team of
expert stakeholders.
Feasibility and Appropriateness
Feasibility for the proposed DNP project has been determined based on concern from the
administration and the director of the labor and delivery unit at the clinical practice setting. There
has been a voiced concern about the rising rate of pregnant women with OUD who have been
treated with MAT during pregnancy presenting for delivery in the labor and delivery unit. A
desire has been expressed in developing a plan to follow-up with these women after delivery to
improve sustained care for the mother-child dyad and decrease the burden this problem has
placed on the community. The facility leadership approved support for this project.
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IRB Approval and Process
The IRB approval process was concluded with ACU before the initial phase project
ensued (see Appendix A). According to instructions in the university’s DNP resource course, the
IRB application followed the approved proposal defense, chair, and committee approval.
Prerequisites for IRB from ACU include proof of completion of an ethics module and education
on human rights while conducting research. The required training for ethics was completed with
proof submitted to ACU on February 2, 2020. The required training on human rights while
conducting research was completed with proof submitted on February 3, 2020.
The required affiliation agreement between the project setting and Abilene Christian
University has previously been finalized. Approval for the DNP student to consider the county’s
local facility for the proposed project has been granted by the administration and education
department at the local practice setting (see Appendix B). The clinical practice setting may also
require specific organization IRB approval. An application will be submitted to the facility upon
ACU approval of the project proposal. There are no known conflicts of interest identified in the
processes of the DNP practice project or between the proposed interdisciplinary team, the DNP
student, and the clinical facility.
Interprofessional Collaboration
An interdisciplinary expert panel of stakeholders associated within the local community
of the hospital practice setting in the Texas Gulf Coast region was to be enlisted to provide
recommendations to the presentation of evidence determined through the GRADE appraisal and
compilation of the EtD findings for the development of guidelines of a formal, comprehensive
postnatal follow-up program for women who have been treated with MAT for OUD during
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pregnancy. The panel of interdisciplinary experts was later presented with the final draft of the
guidelines for evaluation using the PWOUD checklist.
The stakeholder panel was designed to include an obstetrician, a pediatric nurse, a social
worker, an addiction specialist, a community health clinic advanced practice nurse who
specializes in women’s health, the director of the labor and delivery unit and nursing staff at a
local hospital, a counselor from the local Woman’s Center for Domestic Violence, and a grant
writer.
Practice Setting for Evidence-Based Practice
The clinical setting for this DNP project is the community served by an acute care
nonprofit hospital in the southern part of a county in the Texas Gulf Coast region. The hospital
was originally established as a community hospital in 1969 and entered into a partnership in
2014 with a large academic hospital in a neighboring county. This merger with the large
academic hospital opened access to a wide range of high-quality, innovative technologies, a
diverse health care team, and outpatient services for the residents within the community. The
hospital system has a clinic dedicated to pregnancy and maternal health located within the
community. The Regional Maternal Child Health Program affiliated with this hospital system
provides health care and a wide variety of maternal services to women within the area, offering
reduced fees based on need. Permission has been granted to implement the project in the practice
setting.
Although the county shares a border with a larger county where a major metropolitan city
is located, the southern portion of the county where the project setting is located is approximately
51 miles from the metropolitan city’s medical epicenter. The county’s population is one of the
fastest growing in Texas, with a population of over 330,000 residents. The county’s poverty rate
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is 9.89%, with the largest demographic being females age 25–34; females 35–44 are the second
largest demographic living within the poverty level.
Target Population
Although this project’s results will ultimately benefit women who have been treated with
MAT for opioid use disorder OUD during pregnancy during the fourth trimester, the target
population for this DNP project was the expert stakeholder panel who reviewed, critiqued, and
approved the proposed guidelines. The panel was to consist of an obstetrician, a pediatric nurse,
a social worker, an addiction specialist, a community health clinic advanced practice nurse who
specializes in women’s health, the director of the labor and delivery unit and nursing staff at a
local hospital, a counselor from the local Woman’s Center for Domestic Violence, and a grant
writer. Not all panel members invited to participate were able to participate; additional
interprofessional stakeholders were identified during the project’s development.
Risks
There are no discernible health risks to the interprofessional team associated with the
project. Informed consent to participate was acquired from the participating panel members (see
Appendix C). Consent addressed all pertinent information to comply with ethical standards,
including, but not limited to, explanation of the project, expectations of the target population, and
right to withhold consent or terminate participation at any time during the project. Risks of
compromise to the project’s outcomes include the inability to assemble a diverse expert panel of
stakeholders and the lack of participation from the identified expert panel during both face-toface meetings to review recommendations and final guidelines. There are no financial risks
identified. The project implementation cost was estimated to be low if using an online format to
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deliver the research survey. The financial cost of project implementation was the responsibility
of the DNP student.
Benefits
The project’s short-term benefits include enhanced interdisciplinary collaboration
between the members of the expert panel of stakeholders and vested interest for the designated
facility in the care of a quickly growing patient population that requires a unique set of care
interventions. The long-term benefits of acceptance of the project are numerous. Once the project
is completed and guidelines are accepted, a pilot study can be conducted implementing
guidelines and determining the adoption of a formal program into practice. Comprehensive care
of the mother-child dyad will be enhanced, and quality indicators for this population will
improve once the set of guidelines is introduced into practice. The financial costs associated with
postpartum women with OUD, infants with NAS, and the negative effects of OUD on the family
unit can be substantially reduced by implementing a comprehensive multidisciplinary program to
address the needs of the affected population.
Instrument and Measurement Tools
The tools for recording the results of the systematic literature review include the GRADE
system of appraisal table and the GRADE EtD framework table published by the GRADE
working group. Permission to use the GRADE tools for educational and research purposes is not
required by the GRADE working group. The original AGREE II instrument “may be reproduced
and used for educational purposes, quality assurance programmes and critical appraisal of
guidelines” or adapted for individual purposes as long as it is properly cited and the new title of
the tool does not contain the AGREE name (AGREE Next Steps Consortium, 2017, p. ii;
AGREE Enterprise, n.d.; see Appendix D & Appendix E). All three aforementioned tools are
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available for free download on their associated organizational websites; training on use for all
tools is also provided on the organizational websites. It is recommended by the authors of the
original AGREE II tool that at least two experts appraise guidelines; an increase in the number of
appraisers will increase the reliability of the results (AGREE Next Steps Consortium, 2017).
The new PWOUD checklist follows the format of the original AGREE II tool, which is
comprised of a seven-point Likert scale ranging from 1 having the value of strongly disagree to a
7 having the value of strongly agree to rate 23 key points divided into six domains; two
additional overall guideline ratings are addressed following the domain assessments (AGREE
Next Steps Consortium, 2017). Like the original AGREE II tool, the new PWOUD Likert scale
is a statistical tool that will allow qualitative data to be measured on a quantitative scale by
assigning numerical values to expert stakeholder opinions expressed during the review of the
proposed program guidelines. Two versions of the PWOUD instrument were used: first, during
the formative Delphi rounds, a version omitting the two overall guideline ratings of the original
AGREE II tool was used; and secondly, during the final review and acceptance of the
comprehensive program phase, the PWOUD instrument included the overall guideline ratings to
designate acceptance of the guidelines.
The domain scores are determined individually by determining the sum of individual key
points within each of the six domains and calculating the percentage of agreement for each
domain in order to score the tool (AGREE Next Steps Consortium, 2017). The percentage for
each domain score is determined by subtracting the minimum possible score from the obtained
score, then dividing this amount by the maximum possible score minus the minimum possible
score and multiplying the quotient by 100. The following criteria can be followed to interpret
domain scores. “Considering all domain scores: Users can create a threshold across all six
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domain scores based on consensus or decisions by leadership [e.g., high-quality guidelines are
those with domain scores that are all >70%”]; AGREE Next Steps Consortium, 2017, p. 10). The
original AGREE II tool is accompanied by an instruction manual, which provides a descriptor
for each domain, instructions on where to search for information needed for each item in a
domain, and advice on how to rate each item (AGREE Next Steps Consortium, 2017).
Data Collection and Management and Analysis Plan
All data collected during the process of project implementation and analysis is stored as
de-identified data. The data was stored in a secure Google drive provided by ACU under the
DNP student’s name. Data will become the property of the university in case access is needed at
a future date. This drive storage system will be provided by the online graduate school for
doctoral student research data and supported by the university’s information technology (IT)
department for security purposes. It will be kept for the minimum required time according to IRB
guidelines.
This DNP scholarly practice program does not require statistical analysis. Qualitative
analysis of literature review and grading of evidence will be recorded on the appropriate tools
provided from the GRADE working group website. Scores from the PWOUDtool will be
analyzed using the formula provided in the original AGREE II tool instruction manual.
Timeline
The timeline for this DNP project is represented in the table in Appendix F. Initiation of
the project began at the time of enrollment in the scholarly program at ACU in June of 2018 and
will commence at the time of the projected completion of the program in October of 2020. The
practice project clinical site was secured in August of 2018. Draft composition of Chapters 1, 2,
and 3 began in September of 2018. The first public defense of the proposal was completed in late
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March of 2020. Once the proposal defense was accepted, approval from the IRB was initiated
with the approval in early May of 2020. Upon approval, the DNP project’s implementation phase
began with a systematic literature review and grading of evidence. The results were completed
and presented to the expert interdisciplinary panel of stakeholders in June of 2020 for the first
Delphi study round of input. From these findings, formal guidelines were developed during the
period from June to August of 2020. The second round of Delphi study methodology to present
the formal guidelines to the panel commenced in August of 2020. Writing the fourth and fifth
chapters of the DNP project occurred during a simultaneous period from June through August,
culminating in September of 2020 during the DNP II course. The final defense was scheduled for
October of 2020.
Chapter Summary
In response to a known gap in the transition of care during the postnatal period for
women with OUD who were treated with MAT during pregnancy, the need for a formal,
comprehensive program to follow-up with the mother-child dyad was determined. The purpose
of this DNP practice nonexperimental project was to compile best practice evidence from
scholarly sources and professional and government organizations into an EtD framework, which
was appraised by an expert panel using the PWOUD tool to create a set of guidelines for the
comprehensive care of postnatal women who were treated with MAT for OUD during
pregnancy. This set of guidelines can ultimately serve as a grant proposal for a pilot study to
contribute to knowledge regarding the care of this population and ultimately improve outcomes
for the mother-child dyad.
Numerous interventions will be required to provide comprehensive care for postnatal
women with OUD. The GRADE method of appraisal to analyze literature, the GRADE EtD
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framework to recommend interventions, and the acceptance of a set of guidelines using a Likert
scale with minimum-maximum ratings to support credibility will comprise a process that can be
used to evaluate multiple interventions in one concise review. These methods are an appropriate
system to critically assess existing best evidence with the goal of developing a set of effective
clinical guidelines for this practice problem to address the needs of postpartum women with
OUD and their infants.
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Chapter 4: Results
Corresponding with the rising rate of opioid use across the nation, the number of
pregnant women with OUD is increasing at alarming rates (Brogly et al., 2018; Haight et al.,
2018). Current best practice for these women is to follow a treatment plan that incorporates MAT
during pregnancy to maintain a steady dose of opioids in the maternal-fetal bloodstream and
avoid dangerous withdrawal symptoms in the mother and fetus (ASAM, 2015; Park et al., 2012).
At a community hospital in the Texas Gulf Coast region, a gap in practice has been found to
which there is no formal structured follow up for postnatal women who have been treated with
MAT for OUD during pregnancy. This gap in practice leaves this population of women at high
risk for relapse to opioid use during a period that is characterized by numerous physical, social,
and psychological complexities (Baldacchino et al., 2014; Schiff et al., 2018).
This DNP clinical guideline development process used best evidence-based literature,
professional standards, existing program models, and expert input from an interdisciplinary panel
of stakeholders to create a set of guidelines for a formal, comprehensive postnatal follow-up
program for women who have been treated with MAT for OUD during pregnancy. This clinical
guideline development project’s goal was to develop a set of clinical guidelines recommended by
an expert panel. These guidelines will lead to enhanced nursing care for the postpartum women
and improve outcomes for the mother-child dyad. Further explanation of the design of the DNP
nonexperimental evaluative project is explained in this chapter and includes the objectives and
steps taken, appropriateness of the chosen methodology, role of the interdisciplinary team to
promote interprofessional collaboration, description of the practice setting, feasibility of the
timeline for the project, projected budget for executing the project, and the institutional review
board (IRB) process for the chosen facility and Abilene Christian University (ACU).
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Purpose of the Project
This scholarly DNP project’s purpose was to utilize best evidence-based literature,
professional guidelines, and theoretical models to design a guideline to serve as a basis for a
comprehensive postnatal program for postpartum women with OUD to reduce the propensity for
relapse and improve the mother-child dyad. The guideline would be used to determine if the
opinions and input of an expert panel consisting of an interprofessional team would facilitate the
development of the clinical practice guidelines for the target population. This project addressed
the problem of the lack of follow-up for OUD in the postpartum period, also termed the fourth
trimester.
Discussion of Demographics
A convenience sample was deemed appropriate for this study because the invited experts
were already known to be qualified, had already expressed interest in participation, and had
willingly provided email addresses as a means of contact. An invitation email was sent to
prospective participants (see Appendix G). Inclusion criteria was that the participant is
considered an expert in a profession relevant to the study, and they did agree to participate by
completing the demographic portion of the study.
The project’s target population was a panel of experts from multiple disciplines that hold
an interest in the care of the postpartum women with OUD who were treated with MAT during
pregnancy. All panel participants were practicing providers from disciplines within health care,
mental health, and community services domains. Of the seven participants that completed all the
study components, two are in the field of addiction services, two specialize in women’s health,
one specializes in mental health, one in pediatrics, and one is in social work. The panel consisted
of three doctoral and four master’s prepared members. Several of the panel members hold
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degrees in more than one discipline. One holds a master’s degree in psychology with a doctorate
in addiction psychology, and six hold degrees in nursing. Of the three nurses, one also holds a
degree in addiction services, one in mental health, and one in social work. The cumulative
number of years of experience of the panel members was 118. All panel members were residents
of the target community.
Data Analysis
Data analysis of this DNP project included data derived from each of the multiple steps
involved in the project methodology. Data was collected from the rapid literature review,
GRADE summary of evidence table, GRADE EtD framework, an interdisciplinary expert panel
of stakeholders, and the PWOUDLikert scale. The PWOUDLikert scale checklist was used
throughout the Delphi rounds scored using the method established by the authors of the tool and
provided a means to measure data. An online survey generator was used to record responses.
SurveyMonkey is a secure format that provides for anonymous responses and simple data
analysis and presentation (Abd Halim et al., 2018). Permission from SurveyMonkey to use the
format for academic research was granted (see Appendix H). Five main objectives were to be
met using the design of the project. The first and fifth objectives each included two steps. The
program design project was completed with the listed objectives in mind, including the following
steps.
Objective One
Literature Review With GRADE System of Appraisal. The project’s first objective
commenced with a systematic thematic literature review from evidence-based practice literature
and guidelines from both professional and governmental agencies for the management of OUD
during the postnatal period. Due to the vast amount of research rapidly emerging to combat this
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practice problem, I found it difficult to meet the components of an inclusive systematic review in
the allotted DNP program’s timeframe. Although systematic reviews are helpful to conduct
research to support evidence-based practice, they should be exhaustive and can result in
incomplete analysis when the researcher(s) are unable to devote the necessary time and resources
to complete the reviews (Hartling et al., 2017). To decrease the risk of producing an incomplete
review of the evidence, I determined it would be more beneficial in meeting the purpose of this
DNP project within the allotted timeframe to focus research on three main interventions
reoccurring throughout the literature search (see Appendix I).
Rapid reviews are endorsed by the World Health Organization (WHO) and are well
suited for time-sensitive tasks such as guideline development and decision-making regarding
recommendations as they provide concise and focused information on relevant topics (Hartling et
al., 2017; Hartling et al., 2015; Langlois et al., 2018; Tricco et al., 2017). Rapid reviews are
intended to address specific end-users rather than contribute to general knowledge. Hartling et al.
stated, “rapid products are often conducted to help a specific end-user make a specific decision in
an identified timeframe; therefore, the reviewers need to make decisions about what they can
provide in the time allowed” (2017, p. 19). Existing professional guidelines to care for
postpartum women with OUD were considered as examples of working models using evidencebased interventions. Grey literature such as policies, procedure manuals, guidelines, conference
recordings, dissertations, theses, and factsheets was examined to add validity to the
recommendations of best evidence to increase prolonged sobriety for the mother and improve
family dynamics. The GRADE system of evidence of appraisal was used to evaluate the quality
of the evidence. An evidence table was prepared to use when developing the guideline draft (see
Appendix J).
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Objective Two
GRADE EtD Framework. To build on the GRADE method of appraising the strength of
evidence, the GRADE working group EtD framework was used to guide the expert panel’s
decision process. The GRADE approach to literature synthesis, appraisal, and transformation to a
decision framework was found to be a much more extensive process than it first appeared. In a
qualitative study of user experience with GRADE, it was discovered that the program presented
multiple challenges with applicability for public health care policy and guideline development.
According to Rehfuess and Akl (2013), these challenges were based on the complexity and
multiple variables involved with the care of specific populations, including “(i) complexity of
public health interventions, and (ii) choice of outcomes and outcome measures” (p. 9). Rehfuess
and Akl (2013) also suggested the GRADE process is “not all-inclusive enough to apply to
disciplines encompassing psychosocial domains due to the (iii) ability to discriminate between
different types of observational studies, and (iv) use of non-epidemiological evidence” (p. 9).
The GRADE guideline process and EtD framework are difficult for users without timeconsuming training on the product due to complexity and terminology (Rehfuess & Akl, 2013).
Many users of the GRADE process have expressed the desire for more simplified guidance and
expanded options to rating the quality of evidence of psychosocial health interventions (Rehfuess
& Akl, 2013).
Objective Three
Development of the Final Report of Guidelines. The third objective in the
methodology was achieved by presenting a draft of evidence and recommendations to the expert
panel of stakeholders. Theoretical models and guidelines from current recovery programs for
mothers with OUD were reviewed and considered as examples when formatting the

62
recommendations. The Delphi method was used to gain consensus of group opinion on
recommendations for guideline development. This method was appropriate to gain input from
the panel members on the guideline recommendations. The PWOUDAGREE II checklist was
used to collect both qualitative and quantitative data during this phase of the project to determine
if further revisions were needed.
The top three interventions (use of an interprofessional, multidisciplinary team; home
visits; and standardized checklists) discovered during the review of current guidelines and
subsequent literature review were used as the basis for the draft of the guideline
recommendations. The objective of the guideline was to serve as a foundation to
construct comprehensive guidelines for a 12-month follow-up program for the care of
postpartum women with opioid use disorder (OUD) who were treated with medication assisted
treatment (MAT) during pregnancy. The guideline proposed that the use of a multidisciplinary
team, home visits, and checklists as interventions would meet the purpose of providing a
foundation for future program development. The guideline included pertinent information on
stakeholder involvement.
Objective Four
Final Report. Objective four was to formalize and develop a final report based on the
results of Delphi rounds to include the structured, evidence-based process guidelines, proposed
formative and summative goals and milestones, and a proposed budget (see Appendix K).
Because the overall outcome of the project served only to prepare a limited foundation intended
to be used for future guideline development, proposed formative and summative goals and
milestones and proposed budget were not included in the final report. The draft of the
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recommendation guidelines was edited to include input from the expert panel resulting in a
finalized report.
Objective Five
Guideline Recommendations. The final guideline recommendations were to design a
formal, comprehensive program for postpartum women with OUD who were treated with MAT
during pregnancy using the following three interventions as a foundation for development: the
use of a multidisciplinary team, home visits by a health care provider, and the use of
standardized checklists to form a foundation for care of the mother-child dyad. Evidence was
provided to support these interventions. Psychosocial, socioeconomic, and physical health issues
can be improved through collaboration between multiple disciplines. Home visits or “check-ins”
using texting or phone calls can give the health care provider a look at the home environment
and interrelationship dynamics in the home. Adding this dynamic to care for this population can
give the provider a better sense of the needs of the client. Checklists can be used to accurately
document assessments and ensure all aspects of care are addressed. They can also be used as
tools to measure improvement or discover areas for further examination.
Results of the PWOUDChecklist
Two Delphi rounds using the PWOUDchecklist adapted for SurveyMonkey were
completed. After the first round, scoring and comments from the completed PWOUD checklist
served as a basis for revisions of the guideline. Three participants provided comments during the
first round of the Delphi study. Two were agreement statements. One participant stated,
“Excellent, the topic is pertinent to today’s society.” Another participant stated,
Opioid addiction is a problem across society. This practice guideline will be useful in an
effort to provide supports for mothers and their newborns and will facilitate contact that
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may help bridge the gap between postdelivery and home discharge and clinic provider
visits. Newborns will have gains not previously experienced through increased efforts in
maternal bonding and care.
One panel member provided a comment addressing the need for clarification of items within the
guideline corresponding to PWOUDitems. The guideline was revised based on the following
input provided by this panel member.
The author compiled a strong collection of supporting evidence to guide [the]
development of what would likely be a solid perinatal monitoring program for both the
mother and child. While the objectives of the guideline are initially somewhat
nonspecific, particularly regarding outcomes assessment for the child, the bulk of the
proposal becomes, for the most part, self-explanatory and the consideration that was
taken in both completing the background research and developing the resultant
recommendations is apparent. My main concern with the document is MAT does not
refer to “medication avoidance therapy.” This acronym is known in the addiction field to
designate “medication assisted treatment.” Please perform a web search on medication
avoidance therapy. You will find the term is not significantly used; however, medication
assisted therapy is widely known.
Additionally, items that were scored lower than strongly agree on the PWOUDchecklist were
revised.
Revisions included additions to the guideline presentation. Further discussion of panel
members being identified as anonymous experts in multiple disciplines included mental health,
addiction services, registered nurse leadership, social work, women’s health, pediatrics, and
community services. The end target population was identified as postpartum women with OUD
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who were treated with MAT during pregnancy. It was noted that the future development of a
formal program would include the views and preferences of the end target population. Criteria
and methods for selecting evidence for the literature review and linking results to
recommendations were included in the guideline. Upon suggestion from a panel member, it was
decided to change the terminology in the guideline from “medication avoidance therapy” to
“medication assisted treatment.” All aspects of the PWOUDchecklist were included in the
guideline recommendation.
The checklist was scored during both rounds. The Agree Enterprise website provides an
instruction manual to separately score each of the six domains on the PWOUDchecklist. There is
not a total score for the entire checklist, rather a score for each domain. The scores of all
individual items in a single domain are added together and calculated using a formula to
determine an overall percentage rating for the domain.
The instructions for the tool do not designate a percentage at which consensus is said to
be met, leaving this for the user to determine. For the purpose of this guideline project,
consensus was determined on the final Delphi round by asking the panel to rate the overall
quality of evidence and if they would recommend the guideline for use to develop a
comprehensive program. In respect to the first Delphi round, the scores of each of the six
domains increased or remained the same with the final presentation of the guideline. Both rounds
resulted in a percentage consensus of 90% or greater on all six domains. The lowest score on the
first round was 90% for domain six, editorial independence; the highest score was 100% for
domain four, clarity of presentation; the median score of all domains on round one was 95.5%.
For the final round, the lowest score was 96% for domain six, editorial independence; the highest
score was 100% for domain four, clarity of presentation; and the median score was 98%. The
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percentages of consensus for each round of the Delphi study are recorded in the following figure
(see Figure 2).
Figure 2
Percentage of Consensus on PWOUD Guideline Delphi Rounds
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Note. Consensus of agreement is measured in percentage.
Question Guiding the Inquiry
The PICOT question guiding the research was: Will an interprofessional team be able to
develop clinical practice guidelines for a program to follow women treated for opioid use
disorder during pregnancy with medication avoidance therapy after birth? The methodology used
during the implementation of the project showed that an interprofessional team was able to
develop clinical practice guidelines for a program to follow women treated for opioid use
disorder during pregnancy with medication avoidance therapy after birth. The guidelines
developed by the team were not all-inclusive for a formal, comprehensive program for the
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subject population but can be used as a foundation to develop a more detailed program further.
The findings of the PWOUDchecklist to evaluate the formal guidelines presented to the panel
resulted in a consensus scoring of 90% or above on all six domains. The panel members were
100% in agreement that the presented guidelines were acceptable as a foundation to base a more
comprehensive program.
Reliability and Validity
Reliability and validity of the findings were supported by the methodology and tools used
to conduct this DNP project. Although the methodology resulted in a positive correlation to the
research question guiding the project, the tools used during the process were met with challenges
and adjustments were made. Systemic reviews on topics with vast amounts of new research can
take large amounts of time and resources to conduct. Rapid reviews are not as time-consuming or
exhaustive as systematic reviews, however, they are effective at synthesizing evidence for
guideline development and health care decision-making (Hartling et al., 2017; Hartling et al.,
2015; Langlois et al., 2018; Tricco et al., 2017).
Tools from the GRADE working group are endorsed by the WHO and have been tested
extensively for reliability and validity by various research-based organizations throughout the
world (Alonso-Coello et al., 2016). The GRADE tools are structured to be best applied to more
extensive review and guideline development projects than were conducted in this DNP project.
Because the review subject contained psychosocial and mental health dynamics, the GRADE
method of determining levels of evidence was not appropriate for this study, as the method
automatically downgrades for any research that is not a randomized study (Goldet & Howick,
2013). The GRADE approach to literature synthesis, appraisal, and transformation to a decision
framework was found to be a much more extensive process than it first appeared. In a qualitative
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study of user experience with GRADE, it was discovered that the program presented multiple
challenges with applicability for public health care policy and guideline development (Rehfuess
& Akl, 2013). The PWOUDchecklist, coupled with a Delphi methodology, produced a reliable
means to gain consensus on guideline assessment.
Chapter Summary
This DNP project investigated whether an interprofessional team would be able to
develop clinical practice guidelines for a program to follow women treated for opioid use
disorder during pregnancy with medication avoidance therapy after birth. The project used a
multistep methodology including a rapid review of literature, grading of the evidence,
completing an evidence to decision framework, compiling a draft of recommendations that were
presented to an expert panel through two Delphi rounds and the PWOUDchecklist, formulating a
final guideline, and gaining consensus of agreement from the expert panel. The results of the
project did show that an expert panel of expert stakeholders could generate consensus on a
guideline to develop a comprehensive program for postpartum women with OUD who were
treated with MAT during pregnancy. Chapter 5 further discusses the study’s findings and
interpretation as it applies to leadership and the essentials of doctoral education for nurses.
Recommendations for future research will also be discussed.
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Chapter 5: Discussion of Findings, Recommendations, and Conclusions
The purpose of this DNP project was to utilize best evidence-based literature,
professional guidelines, and theoretical models for the design of a comprehensive postnatal
program for postpartum women with OUD who were treated with MAT during pregnancy. The
project used a multistepped methodology including a review of literature, grading of evidence,
presentation of a guideline draft to an expert panel of stakeholders in the care of the end target
population for input through Delphi rounds with the PWOUDchecklist. The expert panel
provided feedback to base revisions of the guideline draft to a final document that was presented
to the panel for consensus of acceptance. The panel consisted of seven interdisciplinary experts
practicing in the fields of nursing, addiction services, women’s health, mental health, pediatrics,
and social work. Two rounds of the Delphi study with the PWOUDchecklist were completed
resulting in group consensus to adopt the guideline. The interpretation and inference of the
findings of this project are discussed in this chapter. An analysis for leaders will be presented,
and the relationship between the findings and the eight DNP essentials will be examined.
Recommendations for future clinical practice and research will be included.
Interpretations and Inference of the Findings
The research question guiding this project asked if an interprofessional team would be
able to develop clinical practice guidelines for a program to follow women treated for OUD
during pregnancy with MAT during the postpartum period. Several steps were taken to
determine the outcomes of the research question. Every step of the methodology revealed
findings that related to the outcome of the project. Certain steps resulted in more positive
conclusions, specifically, the literature review, Delphi rounds, and use of the PWOUDtool to
measure consensus. Findings from the primary and secondary literature reviews substantiated the
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necessity for models of care for postpartum women with OUD who were treated with MAT
during pregnancy. Three main interventions were determined to best serve as the foundation for
further development of a larger program. These interventions are a multidisciplinary team to
guide care, home visits to assess and provide care, and checklists to document care. Other steps
resulted in inconclusive or inauspicious outcomes such as the GRADE table of evidence and EtD
framework. The overall goal of the project was to create a formal, comprehensive follow-up
program for postnatal women with OUD who were treated with MAT during pregnancy to
address the physical, psychosocial, and environmental needs of the population to improve the
mother-child dyad. This project’s goal to develop a comprehensive set of guidelines to care for
the target population through an expert interdisciplinary panel’s input and consensus was
partially achieved. The project’s results showed that the use of an interprofessional panel of
experts could be used to develop a guideline; however, it was determined that the development
of a formal, comprehensive program for the target population was not feasible within the scope
of this DNP project.
A GRADE table of evidence was completed to summarize the results of the rapid review
of the literature. The findings of the table of evidence were inconclusive. Within the GRADE
framework, research must be categorized as randomized trials or observational studies. Much of
the population health, mental health, and substance abuse research included in the rapid literature
review included observational or nonrandomized studies. The GRADE program downgrades the
quality of evidence for any evidence not designated as a randomized study, automatically
labeling the work as low-grade evidence (Goldet & Howick, 2013). Additionally, there are no
provisions to incorporate expert opinion or grey literature; therefore, they are not considered in
the GRADE summary of evidence or the EtD frameworks. Information gained from sources such
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as professional guidelines, government agency policies, fact sheets, and expert clinician
recommendations were excluded from the review and used only as unofficial resources to
substantiate the evidence.
I used the EtD framework to track the project implementation progress, but the product
was not disseminated to the expert panel members. Although being excellent for the tasks
associated with formulating clinical pathways and health care policies, utilization of the entire
program requires extensive time, training for both researcher and end-user, and requires
substantial financial resources to upgrade to a professional product. The GRADE EtD program
would be a valuable resource for more extensive projects. This program could contribute to the
future development of a formal, comprehensive program to provide care to postpartum women
with OUD.
The findings showed evidence that a multidisciplinary team could provide input from
various perspectives on the care of the mother-child dyad, leading to a more comprehensive
foundation on which to base a formal program for the target population. The multidisciplinary
team reached a consensus on an initial guideline to design a more comprehensive program.
Consensus was achieved in two Delphi rounds using the PWOUDchecklist. The combination of
both methods proved to be beneficial to making population care decisions and could contribute
to future initiatives by nursing leadership. It also indicated that nurse-led strategies incorporating
collaborative interdisciplinary care could meet the needs of this population.
This project contributed to existing nursing knowledge regarding both the care of
postpartum women with OUD and the use of an expert panel of interdisciplinary stakeholders to
guide the development of a program to meet the complex needs of this population. The
exponentially growing opioid epidemic has triggered vast research on the subject over the past
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few years. Although much research has been conducted on care pathways for those affected by
opioid use, the research on diverse care for special populations such as postpartum women with
OUD has not been as extensive (ACOG, 2017; Hadland et al., 2020). This project revealed that
much more research is needed to reduce the propensity for relapse for women with OUD and to
improve outcomes of the mother-child dyad.
Limitations
This DNP project was met with several limitations. The first limitation manifested before
the implementation of the project. As previously discussed, the setting of the project was to be a
local community hospital where there had been an increase in the number of deliveries to women
with OUD who were treated with MAT during pregnancy. The majority of these women
obtained care from a local physician who was on staff at this hospital. The physician was
providing obstetrical care while treating them with MAT for OUD. There was a need for a
postpartum program for this population since many of these women were lost to follow up after
discharge from the hospital. Originally the panel members were to include this physician, select
members of his clinic staff, and employees of the labor and delivery unit and social services
department of the hospital. During the proposal writing process of this project, the physician
unexpectedly expired and the practice was closed. Other physicians affiliated with the hospital
system shared obstetrical care of the women until delivery, but there were no physicians to
continue MAT. The sudden loss of the physician not only became a limitation to the initial plan
for the DNP project but also brought an even greater need for community-wide care of
peripartum women in the community. The project was modified to include interprofessional
experts from the entire community who now held a stake in this population’s care.
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The project’s methodology presented an unanticipated limitation to the timeline
concerning implementation. The literature review became more time intensive than planned.
With opioid misuse and addiction being a pressing issue in the health care and political arenas,
the amount of current literature is massive and growing rapidly. It was determined that an
exhaustive systematic review on best evidence-based practice for the postpartum care of women
with OUD should be the singular methodology of a DNP project instead of one of many steps to
implementation. Instead of a systematic review, a rapid review was incorporated into the
methodology, resulting in concise evidence to support evidence-based practice interventions to
serve as a foundation for a more detailed program at a later date. The GRADE EtD framework
also became a limitation due to its complexity and extensive training required to use. The
program required interaction between all panel members during the multiple processes involved
in completing the framework, with training required to manipulate the program (Alonso-Coello
et al., 2016).
The most significant limitation resulted from the outbreak of the COVID-19 pandemic,
which limited access to the panel of interdisciplinary experts. Because of social distancing
imposed during the COVID-19 pandemic occurring at the time of this DNP project
implementation, it was not feasible to implement the full GRADE EtD guideline development
process due to limited face-to-face interactions with panel members. Additionally, many of the
panel members were under strict time constraints due to excess patient care workload or were
directly experiencing health complications from the disease itself. Thus they were unable to
devote the time and effort needed to be trained on the use of the GRADE product. The training
for the EtD program was considered to be too arduous for the panel during this time. The EtD
framework was used to develop the rough draft of the guideline, but a streamlined guideline
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development process was used with the panel members, which did not require additional training
for the panel.
Implications of the Analysis for Leaders
This project has shown that nurse leaders have the ability and the responsibility to
develop strategies to address the opioid epidemic. In particular, the profession of nursing is wellsuited to provide care and develop pathways to care for affected populations with diverse
psychosocial needs such as postpartum women with OUD. Since the inception of the profession,
nursing has been considered to have a foundation built on caring and forging healing
relationships to bring clients to a place of optimal physical, spiritual, and emotional health
(Adams, 2016). Nurse leaders have the qualities and education to make judgments that result in
effective recommendations to lead guideline development teams to care for the complexity of the
target population. Nursing leaders, with knowledge of all dimensions of wellness, are in a prime
position to lead multidisciplinary teams to develop programs aimed at healing the whole
person—spiritually, emotionally, and physically.
Leadership is responsible for the continuing education of those they lead; as new research
reveals the need for systemic cultural change, nurse leaders should initiate endeavors to ensure
their constituents are educated on ways to achieve transformation to a judgment-free
environment. Many postpartum women with OUD have expressed the behavior and demeanor of
health care professionals has left them feeling shame, guilt, and inferiority (Cheng et al., 2016;
SAMHSA, 2018; Schiff et al., 2018). Educational programs that can reduce the stigma nurses
may be inadvertently portraying to these women should be a priority of nurses in leadership.
In the role of nursing leadership, the DNP nurse should be active in advocating for health
care policy to eradicate the disparities and inequalities of underserved populations (Moran et al.,
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2020). Women with OUD face many obstacles in gaining the care they need to maintain sobriety
and flourish in daily life. They often feel powerless to change their financial, environmental, and
psychosocial conditions. Pregnancy is generally covered by some form of insurance, but most
public coverage ends after delivery, leaving women without private insurance without coverage
for health care costs. Even with private insurance, coverage for substance abuse or mental health
is often limited. Nurse leaders can lobby initiatives aimed at extending the time for Medicaid
coverage during the postpartum period, which could decrease the incidence of postpartum OUD,
anxiety, depression, suicide, and opioid overdose by improving continued access to health care
services for postpartum women with OUD.
Suggestions for applying the findings of this research to clinical practice can be grounded
in the DNP Essentials for the Doctoral Education for Advanced Nursing Education Practice,
which provides a model for advanced practice nursing (American Association of Colleges of
Nursing, 2017; Zaccagnini & White, 2017). During this nurse-led guideline development project
to provide a foundation for the care of postpartum women with OUD who were treated with
MAT during pregnancy, an interdisciplinary team of experts was able to come to an agreement
on a plan to care for the mother-child dyad. Application of the findings of this project will be
discussed as they relate to the eight DNP Essentials.
Evidence-Based Findings and the Relationship to the DNP Essentials
Essential I: Scientific Underpinnings
During this DNP project, the research provided evidence that treatment for postpartum
women with OUD requires more than medically treating a disease. Care of the postnatal woman
incorporates treating the whole person—spiritually, emotionally, and physically; it also includes
treating the infant and intervening to improve the mother-child dyad. The combination of
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evidence-based science of medicine with philosophical, ethical, and theoretical-based nursing
provided a model to address all dimensions of a human being to meet the unique set of needs of
postpartum women with OUD. Just as the interdisciplinary team of experts merged knowledge
from various disciplines to reach a consensus on the guideline presented, the subject matter of
this DNP project required a merging of scientific medical knowledge of addiction and MAT with
philosophical knowledge of the client’s beliefs, values, and emotions to provide holistic care.
Results of this research reiterated that nurses are often the front-line providers for patient
populations, especially in areas of community health. In a program to care for postpartum
women with OUD, the DNP would be the eyes and voice of this population by serving as leaders
on multidisciplinary teams developing care models for these women and their infants.
Providing care for this population is laden with instances where ethical and analytical
judgment forms the basis of decision-making. This research has shown that several dimensions
influence the propensity for relapse in these women; there is no unequivocal answer that serves
the population as a whole. For instance, if a woman admits to relapse, does this mean her
children should unquestionably be removed from her care? Does this mean she should be
dismissed from the program? Does this mean she should be incarcerated in jail or inpatient
rehabilitation? These are questions that the DNP must analyze and judge when providing face-toface care for the postpartum women with OUD, whether the DNP is leading the multidisciplinary
team or whether the DNP is providing input for the design of a program to care for the target
population.
Scientific underpinnings of nursing are guided by science blended with theory
(Zaccagnini & White, 2017). The theoretical framework guiding this DNP project was the
opponent process theory (OPT), which explains how the person with OUD sees risky opioid
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misuse as a reward rather than an action that can result in negative consequences; the fear of
repercussions is replaced with feelings of relief (Koob, 2020). The nurse must understand the
physiological changes of addiction on the body are coupled with emotional and behavioral
manifestations that skew the client’s ability to differentiate between negative and positive
reinforcement. The postpartum women with OUD often live with the effects of past trauma and
abuse, which has contributed to a history of substance abuse as an escape mechanism. It is
natural for these women to develop cravings leading to relapse when they feel anxious or
desperate (Koob, 2020). By applying scientific and theoretical knowledge, the DNP can plan
integrative care for postpartum women with OUD.
Essential II: Organizational and Systems Leadership
This project took on the organizational systems viewpoint inherent in the DNP essentials,
which examined the entire process of care for postpartum women with OUD who were treated
with MAT during pregnancy. The project first looked at the opioid crisis as it affects the United
States population as a whole, then the problem was broken down so project development could
gain a full understanding of the many dimensions of OUD and the unique needs of the target
population. By approaching the project, and ultimate solution, with an organizational viewpoint,
it is known that all members of the care team, no matter what rank or duty, are responsible for
making the system work effectively (Zaccagnini & White, 2017). From the leader of the
guideline development team to the postpartum women with OUD, all must do their part to
achieve successful outcomes.
During this research, it was decided by the interdisciplinary panel of experts that a
formal, comprehensive program based on foundation guidelines incorporating a multidisciplinary
team approach, home visits, and checklists to track care could meet the needs of postpartum
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women with OUD who were treated with MAT during pregnancy. Future development of a
larger program that addresses the many physical, psychosocial, environmental, and
socioeconomic needs of this population will require organizational and systems leadership
tailored for the role of the DNP. The panel of experts for this project included addiction
specialists, a social worker, and nurses specializing in mental health, pediatrics, and women’s
health. There are many other roles for nurses and other mental and physical health care providers
in a more comprehensive program. Under the direction of nursing leadership, the program could
be staffed with nurses in multiple specialties and with varying certifications. The areas for
certification and training for nurses is immense. As the program grows, nursing leadership can
reach out to community partners creating alliances to provide additional services to further
enhance the care of the target population.
A financial budget will eventually have to be determined to ensure the organization can
operate successfully. Funding will require an expert in monetary acquisition such as a grant
writer. It is recommended that the DNP should assume this responsibility or seek out a
professional grant writer. Financial costs of building a comprehensive program were not
discussed in this project; however, it is believed that funding from government and health care
organizations could provide the money needed to operate such a program. It is estimated that
costs for such a program could be extensive. A similar program in a central Texas city reports
annual costs of up to $400,000 depending on resources available to the program (Cleveland et
al., 2015). This particular program receives funding from grants from SAMHSA and local health
care systems (Cleveland et al., 2015).
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Essential III: Clinical Scholarship and Analytical Methods
This qualitative DNP project utilized several methods to synthesize evidence-based
literature, analyze results, and transfer the evidence to implement a quality improvement
program for the care of postpartum women with OUD who were treated with MAT during
pregnancy. The project further implemented a guideline evaluation as a research method.
According to Zaccagnini and White (2017), different types of qualitative studies can be used to
enhance nursing practice, including “critical social theory, ethnographic studies, grounded theory
research, historical research, phenomenological studies, and philosophical inquiry” (p. 75). This
research fell into two of these categories: critical social theory since the research on a population
(postpartum women with OUD) met with many inequalities and socioeconomic disparities, and
ethnographic research was incorporated in two ways: by including views of the target population
in literature reviews and by gaining commentary from the expert panel.
A review of the literature resulted in development of a guideline based on three evidencebased interventions to provide care to postpartum women with OUD who were treated with
MAT during pregnancy. The literature review contributed to current research by integrating the
three interventions into a care bundle to serve as a foundation for later development of a more
comprehensive program. The evidence was synthesized using the GRADE method of literature
analysis, which did not result in a strong representation of the evidence due to the operational
constraints of the tool. Other tools to critique literature can be used by the DNP to rate the
quality of evidence for health care with a heavy mental or social health basis. The PWOUDwas
used in Delphi survey rounds to rate the guideline drafts until the expert panel of stakeholders
determined a consensus. The use of the tool was determined to be a beneficial aspect of the
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research methodology. The tool could be used for future evaluation of additional guidelines as
the project continues to develop.
Essential IV: Information Systems and Patient Care Technology
Throughout the implementation of this DNP project, the use of information systems and
Internet technology were used to review literature, communicate with expert panel members,
collect and analyze data, and disseminate results. Information systems to care for the target
population were recommended in the literature review. The accepted foundation guidelines
included recommendations to interact with the target population using technology to enhance the
delivery of care. Online searches of publicly available search engines and private databases were
accessed during this project to examine evidence-based literature and general knowledge.
Several online tools were used to critique evidence and develop quality improvement guidelines.
The GRADE evidence table and EtD framework were online information systems used to
facilitate research.
The AGREE II tool was downloaded from an online source available for free to
developers of practice guidelines. An online format of the tool was said to be available but was
not used because the link to the online survey was inaccessible throughout the implementation
process. Instead, the tool was distributed to the expert panel using a secure online survey format
called SurveyMonkey. The format allowed for the AGREE II to be adapted to the PWOUD
checklist and presented as an online survey assessable through an emailed link. A link on the
initial consent directed the expert panel participant to an instructional presentation and a
demographic questionnaire and the PWOUDchecklist. SurveyMonkey also allowed for the
development of analytical graphs and charts and a PowerPoint presentation of the results of the
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survey. This presentation could be used in the future development of a more formal,
comprehensive program for the care of the target population.
One of the essential purposes of meaningful use (MU) is to improve the quality and
safety of patient care and improve outcomes for any patient population across the health care
spectrum (McBride & Tietz, 2016). In addition, MU is meant to improve the coordination of care
among numerous patient encounters, reduce errors and omissions of health care, and provide
patients with access to their medical history and treatment plans (Agency for Healthcare
Research and Quality, 2015). This research found that home visits and using standardized
checklists can improve the coordination of care of the mother-child dyad. One recommendation
to facilitate regular interactions between the health care provider and the client was to use cell
phones for check-ins, reminders, communication, and education. Electronic checklists can be
used to provide consistency in assessment, documentation, and guarantee a standardized criterion
to which outcomes can be measured and evaluated.
Essential V: Health Care Policy
The aspect of health care policy as it applies to nursing leadership within this DNP
project’s scope using an interprofessional panel of experts to develop a set of program guidelines
can be met by including local and state government officials in the guideline development
process. During the research phase of this DNP project, a member of the Texas House of
Representatives was contacted to inquire about state legislation to address maternal mortality and
initiatives to address OUD during the peripartum period. According to the representative,
numerous bills have been filed by House members that focus on improving maternal health and
seek to provide resources to identify and treat women at risk for poor health outcomes during and
after pregnancy (D. Bonnen, personal communication, March 22, 2019). Doctor of Nursing
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Practice-prepared nurses have an obligation to lobby for legislation that addresses health
disparities and the unique needs of special populations. Several bills can be supported that seek
to establish statewide programs to improve maternal and newborn health for the target
population.
According to the representative, legislative efforts to improve maternal health care in
Texas remain committed to addressing maternal mortality and morbidity (D. Bonnen, personal
communication, March 22, 2019). State and national funds have been set aside for the care of
women, children, and families affected by the opioid epidemic. Advanced practice nurses have
successfully lobbied to create programs for prenatal and postnatal care via telemedicine,
inpatient treatment medical homes for pregnant women with mental and substance abuse
disorders, and training courses that target women of childbearing age to help prevent OUD and
negative outcomes (D. Bonnen, personal communication, March 22, 2019).
Essential VI: Interprofessional Collaboration
This DNP project was based on determining the extent which interprofessional
collaboration could influence the construction of a guideline to care for postpartum women with
OUD who were treated with MAT during pregnancy. All phases of the project incorporated
interprofessional collaboration, from the literature review, which included studies and theoretical
models from multiple disciplines, to the expert panel’s final consensus of the recommendations.
This interprofessional team was able to thrive under the direction of nursing leadership to
successfully collaborate in defining a set of guidelines to provide care to a multidimensional
patient population. Nursing leadership recognized barriers and limitations to communication
within the panel and effectively developed strategies to overcome them. The limitations in
communication resulting from the COVID-19 pandemic social distancing restrictions may have
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reduced the amount of discussion between panel members. However, each member of the
interprofessional team of experts was provided with an opportunity to input comments on the
PWOUDchecklist based on their unique sets of professional knowledge. Through trusting
partnerships centered on mutual respect, the DNP leader has the essential skills and knowledge
to lead practice change interprofessional teams effectively.
Essential VII: Clinical Prevention and Population Health
The interdisciplinary team that participated in this DNP project agreed on the set of initial
interventions as a guideline to develop a more intricate and extensive future comprehensive
program with the goal of providing care for postpartum women with OUD who were treated with
MAT during pregnancy. The outcome of a care pathway for this population is to prevent the
mother from relapsing and help her maintain sobriety. This DNP project was a clinical
prevention and meant to enhance not only the quality of life for this specific population but to
increase the quality of health and outcomes for a much larger domain. By keeping the mother
from relapsing and developing a program rich in interventions to support and improve health
outcomes for the mother, child, family unit, community, and society. This project aimed to
provide care to a target population that serves as the core of the family unit, the foundation of the
next generation, and the status of society’s future. By improving the mother-child dyad in the
present, the future of the next generation is also improved.
The role of the DNP prepared nurse in the fight against substance abuse, in general, is
immense. This is particularly true within the realm of postpartum women with OUD. One of the
main responsibilities of advanced practice nurses is the promotion of physical and mental health
through preventative education (Zaccagnini & White, 2017). Teaching topics pertinent to the
target population include nutrition, breastfeeding, assessment for onset or complications of NAS,
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NAS soothing techniques, infant massage, anger management, stress management, tobacco
exposure, domestic violence prevention, parenting skills, home safety, family planning, and other
individualized teaching needs. Other preventative measures that should be undertaken by the
DNP are those pertaining to the referral of the postpartum woman with OUD to counseling and
mental health service, social services, and community programs that can help improve
psychosocial and socioeconomic obstacles.
Essential VIII: Advanced Nursing Practice
The role of the DNP is evolving every day, encompassing clinical, administration, and
education practice. The problem addressed in this DNP project was the increase in the number of
postpartum women with OUD who took MAT during pregnancy and who were subsequently lost
to follow up in the postnatal period. These women were at risk for relapse and recidivism. The
gap in practice was that there was no formal, comprehensive program for postpartum follow-up
of these women. Findings from this project showed that there is a place for DNP practice in the
clinical, administrative, and educational aspects of the provision of care for postpartum women
with OUD who were treated with MAT during pregnancy. Clinical DNPs have the advanced
clinical judgment and critical thinking skills to provide care at the personal level; DNPs in
leadership have the skills to lead care initiatives and mange operations involved with the
development and maintenance of programs to care for the target population, and DNPs with
educational backgrounds have the knowledge to continue research on innovative care for the
population and to educate the next generation of nurses on the evidence-based delivery of
nonjudgmental and nonbiased care. Doctors of Nursing Practice practicing in all specialties have
the responsibility to lobby for policy changes and value-based care for the mother-child dyad.
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Recommendations for Future Research and Clinical Practice
Each discipline that is involved in the treatment of postpartum women with OUD who
were treated with MAT during pregnancy confronts the complexity of this duty from a differing
viewpoint. Traditionally, each of these disciplines provides their own care pathways and care
structures, creating a fragmented system. The move to collaborative care for the target
population may be difficult, but evidence shows the effort results in improved outcomes for this
population. The recommendation for the future of integrated care for this population is to
research methods to facilitate the merging of health care, mental health, social services, and
community services into a cohesive program. Professional education to a multidisciplinary
workforce is needed to teach methods to provide care in a nonjudgmental way that will reduce
the stigma and shame many women with OUD experience.
This DNP project addressed a very small portion of the research needed to make an
impact on the enormous problem of perinatal opioid misuse that is prevalent in all areas of the
country. It was not possible within the scope of this project to cover the extent of a
comprehensive program to provide care to postpartum women with OUD who were treated with
MAT during pregnancy to improve outcomes for the mother-child dyad. Many opportunities for
future research and guideline development exist in reference to prevention, education, and care
pathways. A comprehensive guideline should outline processes to provide family-centered care
with the goal of improving the mother-child dyad. A program should address outcomes such as
bonding of the mother and child, care of the newborn, parenting skills, child well-being and
safety, nutrition, and breastfeeding. Research should be conducted that leads to decisions on the
development or adoption of checklists to ensure all aspects of care are addressed. Some of these
include substance abuse, mental health, post-trauma distress, NAS and neonatal health, intimate
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partner or other household member violence, housing, transportation, employment, childcare,
and food insecurities. Methods to measure the effectiveness of interventions and assess outcomes
should be designed. Ultimately, a formal, comprehensive set of guidelines should be developed
to provide a 12-month follow-up program to decrease the rates of relapse in postpartum women
with OUD who were treated with MAT during pregnancy and improve the maternal-child
bonding process.
Conclusion
This DNP project analyzed the use of an interdisciplinary panel of expert stakeholders to
develop a foundational set of guidelines for the care of postpartum women with OUD who were
treated with MAT during pregnancy. The goal of the guidelines is to decrease the risk of relapse
for the woman and to improve the quality of the mother-child dyad. The methodology of the
project incorporated a multistep process including a literature review, grading of evidence,
transferring evidence to a decision, formulating a draft of guidelines, presenting the draft to an
interdisciplinary panel of experts through a Delphi process for input, draft revision into a final set
of guidelines, and presentation of the final guidelines to the expert panel for a consensus vote.
Findings of the study revealed that the use of an interdisciplinary panel of experts was a useful
tool to gain input and consensus on a practice problem that is best treated with a collaborative
multidisciplinary approach.
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Appendix B: Letter of Support

XXXXXXXXX, BSN, RN
Director of Education
XXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXX XXXXXX
XXXXXXXXXXX

February 3, 2020
To Whom It May Concern:
This letter is written confirmation of intended support for the project proposed by Lea
Ann Quave regarding the planning and design of a comprehensive program for
postpartum women with opioid use disorder (OUD) who were on medication therapy
during pregnancy. I understand that this project will not involve direct patient contact or
access to private health information.
XXXXXXXXXXXXXX is committed to furthering education and leadership for nurses.
It is my pleasure to support this project, which will contribute to research of a growing
problem in our community and across the nation, as well as prepare nurses to provide
quality care to postpartum women with OUD during a vulnerable time.
I support Ms. Quave in her development of this capstone project to fulfill the
requirements of achieving a Doctor of Nursing Practice designation. If you have
questions or concerns, please do not hesitate to contact me.
Sincerely,
XXXXXXXXXXX
XXXXXXXXXXXXXX, BSN, RN
Director of Education
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Appendix C: Informed Consent

Introduction: Supporting Postnatal Women with Opioid Use Disorder Treated
with Medication Avoidance Therapy
You may be able to take part in a research study. This form provides important information about that
study, including the risks and benefits to you as a potential participant. Please read this form carefully and
ask the researcher any questions that you may have about the study. You can ask about research activities
and any risks or benefits you may experience. You may also wish to discuss your participation with other
people, such as your family doctor or a family member.
Your participation in this research is entirely voluntary. You may refuse to participate or stop your
participation at any time and for any reason without any penalty or loss of benefits to which you are
otherwise entitled.
PURPOSE & DESCRIPTION: The purpose of this research study is to outline evidence-based
contemporary recommendations and define the ideal components of a set of guidelines that could be used
to form a program to address the physical, psychosocial, and environmental needs of the mother with
opioid use disorder who was treated with medication during pregnancy.
You are being asked to participate in a modified Delphi study, which is a systematic polling of the
opinions of an expert panel knowledgeable on a given topic through online surveys in an attempt to reach
group consensus on a given topic. You were selected as a possible participant in this study because you
have been identified as an experienced practitioner who fills a role in developing or supporting the
sobriety and health of women with opioid use disorder who were treated with medication therapy during
pregnancy. Through developing a set of guidelines based on expert opinions, it is hoped that a plan to care
for women with opioid use disorder who have recently delivered infants can serve as building block for
implementing a program design.
If selected for participation, you will be asked to participate in three (3) online sessions provided via
email by the study staff over the course of four (4) weeks. The first session is expected to take ten (10)
minutes; the second session is expected to take twenty (20) minutes; each subsequent session is expected
to take fifteen (15) minutes for a total expected participation time of one (1) hour. During the course of
these sessions, you will be asked to participate in the following procedures:
•

•

•

Session I: Read the recruitment email, access and read this Informed Consent document through
the provided hyperlink below, consent to participation in the study by completing the limited
demographic data, and clicking the “Yes” option at the end of the consent to advance to the initial
page of the survey.
Session II: You will then be asked to view a short five (5) minute online presentation of the
overview of the evidence-based recommendations and complete the Round I Survey as instructed
and submit responses to the specified SurveyMonkey website by the designated due date.
Session III: A approximately one week later, you will receive the Round II survey, which you
will be asked to complete according to the Round II Survey instructions and submit to the
specified SurveyMonkey website by the designated due date.
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•

Session IV: Approximately two weeks later, you will receive the Round III Survey, which you
will complete according to the Round III Survey instructions and submit this to the specified
SurveyMonkey website by the designated due date.

Your responses and information will be encrypted and sent over a secure connection provided by
SurveyMonkey. Through an option provided by SurveyMonkey, responses are received anonymously. All
respondent information including first name, last name, email address, and IP address are excluded from
results.
RISKS & BENEFITS: There are risks to taking part in this research study. Below is a list of the
foreseeable risks, including the seriousness of those risks and how likely they are to occur.
The risks associated with participation in this study are minimal and would be rare if they occurred. The
primary risk with this study is breach of confidentiality. However, as will be discussed further in the next
section, we have taken steps to minimize this risk. If you should feel uncomfortable about participating in
the Delphi study, you can discontinue study participation at any time without repercussions by clicking
the SurveyMonkey link asking you to be removed from the mailing list. All data collected will be stored
in a password-protected computer file in the principal investigator’s (PI) office available only to the PI
and research staff.
You may not experience any personal benefits from participating in this study.
PRIVACY & CONFIDENTIALITY: Any information you provide will be confidential to the extent
allowable by law. Your confidentiality will be protected by ensuring that there will be no identifying
information on any of the data from the Delphi study. Your survey submission will be associated with
your email address, which will be kept in a log that will be stored in a password-protected computer file
available only to the researcher. You will need to be contacted by the researcher via your email address
during the study if you do not respond during the requested time frame between each Delphi round. Some
identifiable data may have to be shared with individuals outside of the study team, such as members of
the ACU Institutional Review Board. Otherwise, your confidentiality will be protected. All data collected
during the process of project implementation and analysis will be stored as de-identified data. The data
will be stored in a secure Google drive provided by ACU under the researcher’s name. Data will become
the property of the university in case access is needed at a future date. This drive storage system will be
provided by the online graduate school for doctoral student research data and supported by the
university’s IT department for security purposes. It will be kept for the minimum required time according
to IRB guidelines.
The primary risk with this study is breach of confidentiality. However, we have taken steps to minimize
this risk. We will not be collecting any personal identification data during the survey. However,
SurveyMonkey may collect information from your computer. You may read their privacy statements here:
https://www.surveymonkey.com/mp/policy/privacy-policy/.
CONTACTS: If you have questions about the research study, the lead researcher is Lea Ann Quave,
MSN, RN, and may be contacted at XXXXXXX XXXXXXXXXand/or XXXXXXXXXX
XXXXXXXXXX. If you are unable to reach the lead researcher, or wish to speak to someone other than
the lead researcher, you may contact xxx xxxxx, DrPH, MPA, MSN, RN, XXXXXXXXX,
XXXXXXXXXX.
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If you have concerns about this study, believe you may have been injured because of this study, or have
general questions about your rights as a research participant, you may contact ACU’s Chair of the
Institutional Review Board and Executive Director of Research, Mxxxx Rxxx, Ph.D. Dr. Rxxx may be
reached at
XXXXXXXXXX
XXXXXXXXXXXXXXXXXXXX
XXXXXXXXX

Additional Information
The expected number of participants to be enrolled in this study is seven (7) to ten (10).
Your participation may be ended early by the researchers for certain reasons. For example, we may end
your participation if you no longer meet study requirements, the researchers believe it is no longer in your
best interest to continue participating, you do not follow the instructions provided by the researchers, or
the study is ended. You will be contacted by the researchers and given further instructions in the event
that you are removed from the study.

Consent Signature Section
For electronic consent to complete online surveys: Do you consent to participation in this study?
Please answer the question by clicking the Yes button below to agree to the terms of this consent, or the
No button below to decline participation. If you click Yes, you will be asked to you enter your last name,
email address and professional designation. Click Yes only after you have read all of the information
provided and your questions have been answered to your satisfaction. If you wish to have a copy of this
consent form, you may print it now. You do not waive any legal rights by consenting to this study.
If you would like to decline participation in this study, please do so by clicking the No button to terminate
this request for consent.

112
Appendix D: PWOUD Checklist (Delphi Round I)
PWOUD Rating of Clinical Practice Guidelines
Rating Scale: (7) Strongly Agree, (6) Agree, (5) Partially Agree, (4) Neutral, (3) Partially
Disagree, (2) Disagree, (1) Strongly Disagree
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.

Domain
The overall objective of the guideline is specifically
described
The health question covered by the guideline is
specifically described
The population to whom the guideline is meant to
apply is specifically described
The guideline development group includes
individuals from all the relevant professional groups
The views and preferences of the target population
have been sought
The target uses of the guidelines are clearly defined
Systematic methods were used to search for
evidence
The criteria for selecting the evidence are clearly
described
The strengths and limitations of the body of
evidence are clearly described
The methods for formulating the recommendations
are clearly described
The health benefits, side effects, and risks have been
considered in formulating the recommendations
There is an explicit link between the
recommendations and the supporting evidence
The guideline has been externally reviewed by
experts prior to its publication
A procedure for updating the guideline is provided
The recommendations are specific and unambiguous
The different options for the management of the
condition or health issue are clearly presented
Key recommendations are easily identifiable
The guidelines provide advice and/or tools on how
the recommendations can be put into practice
The guidelines describe facilitators and barriers to
its application
The potential resource implications of applying the
recommendations has been considered
The guidelines present monitoring and/or auditing
criteria
The views of the funding body have not influenced
the content of the guideline
Competing interests of guideline development group
members have been recorded and addressed

Comments:

SA

A

PA

N

PD

D

SD

N/A
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Adapted from “AGREE II: Advancing Guideline Development, Reporting and Evaluation in
Healthcare,” by M. C. Brouwers, M. E. Kho, G. P. Browman, F. Cluzeau, G. Feder, B. Fervers,
S. Hanna, J. Makarski on behalf of the AGREE Next Steps Consortium, 2010, Canadian
Medical Association Journal, 182, E839-842. Copyright 2010-2014 by The AGREE Research
Trust.
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Appendix E: PWOUDChecklist (Final Round)
PWOUDRating of Clinical Guidelines
PWOUDRating
Domain
Scope and
purpose

Item
1.

The overall objective(s) of the guideline is (are) specifically described.

2.

The health question(s) covered by the guideline is (are) specifically described.

3.

The population (patients, public, etc.) to whom the guideline is meant to apply is
specifically described.

4.

The guideline development group includes individuals from all the relevant
professional groups.

5.

The views and preferences of the target population (patients, public, etc.) have
been sought.

6.

The target users of the guideline are clearly defined.

7.

Systematic methods were used to search for evidence.

8.

The criteria for selecting the evidence are clearly described.

9.

The strengths and limitations of the body of evidence are clearly described.

10.

The methods for formulating the recommendations are clearly described.

11.

The health benefits, side effects, and risks have been considered in formulating
the recommendations.

12.

There is an explicit link between the recommendations and the supporting
evidence.

13.

The guideline has been externally reviewed by experts prior to its publication.

14.

A procedure for updating the guideline is provided.

15.

The recommendations are specific and unambiguous.

16.

The different options for management of the condition or health issue are clearly
presented.

17.

Key recommendations are easily identifiable.

18.

The guideline describes facilitators and barriers to its application.

19.

The guideline provides advice and/or tools on how the recommendations can be
put into practice.

20.

The potential resource implications of applying the recommendations have been
considered.

21.

The guideline presents monitoring and/or auditing criteria.

Editorial
independence

22.

The views of the funding body have not influenced the content of the guideline.

23.

Competing interests of guideline development group members have been
recorded and addressed.

Overall
Guideline
Assessment

1.

Rate the overall quality of this guideline.

Overall
Guideline
Assessment

2.

Stakeholder
involvement

Rigor of
development

Clarity of
presentation

Applicability

I would recommend this guideline for use.

1
Strongly
Disagree

2

3

4

5

6

7
Strongly
Agree

1
Lowest
possible
quality

2

3

4

5

6

7
Highest
possible
quality

Yes

Yes, with modifications

No
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Adapted from “AGREE II: Advancing Guideline Development, Reporting and Evaluation in
Healthcare,” by M. C. Brouwers, M. E. Kho, G. P. Browman, F. Cluzeau, G. Feder, B. Fervers,
S. Hanna, J. Makarski on behalf of the AGREE Next Steps Consortium, 2010, Canadian Medical
Association Journal, 182, E839-842. Copyright 2010-2014 by The AGREE Research Trust.
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Appendix F: Project Timeline

Task

Year

Month

Secure clinical site

2018

August

Compose draft of Chapters 1, 2, 3

2018

Sept–Dec

Compose draft of Chapters 1, 2, 3

2019

Jan–Dec

Complete first public defense

2020

March

Begin literature review

2020

March–May

2020

April

2020

June

2020

June–August

2020

August

Complete 4th and 5th chapters

2020

June–Sept

Schedule final defense

2020

October

Obtain IRB approval for project from ACU and
project site
Present to GRADE and EtD framework findings
to interdisciplinary panel of stakeholders
Develop formal guidelines
Present formal guidelines to interdisciplinary
panel of stakeholders
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Appendix G: Recruitment Email
Greetings:
As a component of completion of a Doctor of Nursing Practice (DNP) program at the Abilene
Christian University, I will be implementing a DNP project to address a particular practice
problem. With an increase in the number of pregnant women in our community on the Texas
Gulf Coast presenting with opioid use disorder (OUD) and treatment with medication avoidance
therapy (MAT) during pregnancy, a need has been identified to reframe interventions to improve
follow up in the postpartum period to decrease the risk for recidivism and relapse. The purpose
of this scholarly DNP nonexperimental prospective exploratory project is to utilize best
evidence-based literature, professional guidelines and theoretical models for the design of a
comprehensive postnatal program for this population. The program design uses an onlinemodified Delphi format to collect data from an expert panel. You are being asked to participate
in this Delphi study in an attempt to reach group consensus on a set of guidelines to structure
care for this population. You were selected as a possible participant in this study because you
have been identified as an experienced practitioner who fills a role in developing or supporting
the sobriety and health of women with opioid use disorder who were treated with medication
therapy during pregnancy.
The project will begin with a systematic literature review from quantitative and qualitative
evidence-based literature to format a set of formal guidelines for the care of a vulnerable
population. The project will also include use of the Grading of Recommendations Assessment,
Development, and Evaluation (GRADE) system of appraisal and the GRADE Evidence to
Decision (EtD) framework to synthesize the evidence and form recommendations for a
comprehensive postnatal follow-up program for women with OUD who were treated with MAT
during pregnancy. Using an online Delphi survey through SurveyMonkey, the compilation of
evidence and recommendations will then be presented to a panel of interdisciplinary stakeholders
from the community in the Texas Gulf Coast region that has seen an increase in pregnant women
with OUD who are being treated during pregnancy for their input and consensus. This program
can provide a structure and process for implementing best practice clinical guidelines for the
management and support of the postpartum mother-child dyad.
If you volunteer to participate in this Delphi study, you will be asked to do the following:
•

•

•

Session I: Read this recruitment email and the provided Informed Consent document,
consent to data collection by clicking to advance the page to the survey, and complete the
limited demographic data. Time commitment is expected to be approximately 10
minutes.
Session II: You will then be asked to view a short five (5) minute online presentation of
the overview of the evidence-based recommendations and complete the Round I Survey
as instructed and submit responses to the specified SurveyMonkey website by the
designated due date. Time commitment is expected to be approximately 20 minutes.
Session III: Approximately one week later, you will receive the Round II Survey, which
you will be asked to complete according to the Round II Survey instructions and submit
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•

to the specified SurveyMonkey website by the designated due date. Time commitment is
expected to be approximately 15 minutes.
Session IV: Approximately two weeks later, you will receive the Round III Survey,
which you will complete according to the Round III Survey instructions and submit this
to the specified SurveyMonkey website by the designated due date. Time commitment is
expected to be approximately 15 minutes.

Time Commitment: Overall, participation in the Delphi study will take approximately one hour.
If you have questions about the research study, please contact me as the DNP student.
Lea Ann Quave, MSN, RN
XXXXXXXXX
XXXXXXXXXXXXX
XXXXXX XXXXXXX XXXXXXXXX
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Appendix H: Permission to Conduct Research Using SurveyMonkey

SurveyMonkey Inc.
www.surveymonkey.com
For questions, visit our Help Center
help.surveymonkey.com
Re: Permission to Conduct Research Using SurveyMonkey
To Whom It May Concern:
This letter is being produced in response to a request by a student at your institution who wishes
to conduct a survey using SurveyMonkey in order to support their research. The student has
indicated that they require a letter from SurveyMonkey granting them permission to do this.
Please accept this letter as evidence of such permission. Students are permitted to conduct
research via the SurveyMonkey platform provided that they abide by our Terms of Use at
https://www.surveymonkey.com/mp/legal/terms-of-use/.
SurveyMonkey is a self-serve survey platform on which our users can, by themselves, create,
deploy, and analyze surveys through an online interface. We have users in many different
industries who use surveys for many different purposes. One of our most common use cases is
students and other types of researchers using our online tools to conduct academic research.
If you have any questions about this letter, please contact us through our Help Center at
help.surveymonkey.com.
Sincerely,
SurveyMonkey Inc.
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Appendix I: Secondary Literature Review

Literature Review of Best Evidence Interventions for Postpartum Women with Opioid Use
Disorder Treated with Medication Avoidance Therapy During Pregnancy
The goal of this rapid literature review is to organize evidence to support the findings of a
previously completed systematic literature review to determine best evidence-based practice for
the follow-up care of postpartum women with opioid use disorder (OUD) who were treated with
medication avoidance therapy (MAT) during pregnancy. The evidence was supported by a
review of existing guidelines from various like-minded organizations providing care to the target
population. The question guiding this literature review was: What main interventions should
form the basis of a guideline for the care of postpartum women with OUD who were treated with
MAT during pregnancy after they are released from the hospital, and what will help them remain
abstinent and on the road to recovery? The results of all the reviewed articles and guidelines
showed the top three best evidence-based practice interventions with good results were
collaborative multidisciplinary management, in-home visits, and assessment checklists to guide
care.
Methodology
A literature review was completed using the online EBSCOhost database provided
through the Margarett and Herman Brown Library at Abilene Christian University. The
following terms were used for the initial search: postpartum, home visits “or” checklist “or”
multidisciplinary team, opioid, relapse. Filters used were full text, scholarly peer reviewed
journal articles, academic journals, substance abuse, and pregnancy. Publications between the
years 2015 and 2020 were included. The initial search produced 9,729 results. After filters were

121
added, 31 articles remained. Duplicate articles were excluded, as were articles published in
countries other than the United States and articles that did not provide relevant information; 13
articles remained and were included in the review.
Review of Literature
Collaborative multidisciplinary management. Collaborative care of the postpartum
women with OUD must address physical, psychological, and socioeconomic issues such as
postnatal health care for the mother and infant, substance use, pharmacological MAT adherence,
housing instability, food insecurity, intimate partner violence, mother-child bonding, and mental
health disorders (Hanson, Saul, Duryea et al., 2019; Hanson, Saul, Vanderploeg et al., 2015;
Harvey et al., 2015; Higgins et al., 2019; Hodgins et al., 2019). Goodman et al. (2015) found that
better outcomes where achieved when care for mothers with substance abuse were treated in a
multidisciplinary manner which included women’s health care, addiction therapy, health
promotion for mother and child, and education to meet the learning needs of the mother. In
addition to collaborative management of the mother, interdisciplinary team care for the infant
with neonatal abstinence syndrome, or the infant with a propensity for complications of maternal
opioid use, has shown to improve health outcomes (Anbalagan & Mendez, 2020). Social services
and family counselors on the collaborative care team provide resource allocation to match client
needs, as well as parenting education that can motivate the postpartum woman to remain sober
(Holbrook & Nguyen, 2015). Increased involvement of social service and child welfare should
be initiated for children at risk (Holbrook & Nguyen, 2015).
In-home visits. Home visits allow the health care team to “meet women where they are”
(Hodgins et al., 2019, p. 586). The Collaborative Outreach and Adaptable Care at Hallmark
Health (COACHH) program in Massachusetts has found check-ins one or two times a week
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through home visits or phone calls to improve outcomes for mothers with substance use disorder
(Hodgins et al., 2019). The home visits allow the provider to assess the home environment and
gain a glimpse of the everyday life of the client to facilitate care based on observation (Hodgins
et al., 2019; Lewis et al., 2017). The Johns Hopkins University family-based recovery model
(FBR) successfully helps mothers with OUD to remain sober by implementing a series of stepdown home visits; the client is seen in their home at three separate 60-minute visits for the six
months of treatment, tapering to once a week visits by the end of the first year postpartum
(Hanson, Saul, & Duryea et al., 2019). Home visits were found to decrease risk of relapse,
increase treatment retention, improve parenting skills of the mother, decrease adverse
involvement of child welfare departments, and reduce subsequent unintended short interval
pregnancies in postpartum women with OUD (Goodman et al., 2015). Home visits can be
supplemented with technology such as smartphones, which have been provided to clients to
facilitate check-ins, send reminders of appointments, complete surveys, provide education, and
facilitate communication (Sanjuan et al., 2020).
Assessment checklists. An integrated needs assessment has been shown to improve
outcomes for the mother-child dyad (Hodgins et al., 2019). Ongoing assessment through
documentation, such as a checklist, provides a means for measuring improvement or reveal
downward trends; thus, improving outcomes for postpartum women with OUD (Goodman et al.,
2019; Hodgins et al., 2019). Following a standardized checklist can prevent the oversight of
important assessments and improve communication of needs to other members of the healthcare
team (Goodman et al., 2019). Items that assess anxiety and stress of the mother should be
included in the checklist since high-stress situations can lead to relapse (Dworkin et al., 2017;
Fallin-Bennett et al., 2020; Hanson, Saul & Duryea et al., 2019; Hanson, Saul, & Vanderploeg et
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al., 2015; Harvey et al., 2015). Mother-child bonding and attachment are important indicators of
family dynamics; lack of a healthy mother-child relationship may indicate psychological issues
that could lead to relapse and should therefore be a routine assessment measure (Hanson, Saul, &
Duryea et al., 2019; Hanson, Saul, & Vanderploeg et al., 2015; Mirick & Steenrod, 2016;
Sanjuan et al., 2020). Socioeconomic assessment should be included in the checklist, such as
lack of transportation, unsafe housing, and food insecurities (Lewis et al., 2017). Postpartum
women with OUD should be assessed for alcohol, tobacco, and other substance use, partner
violence, food insecurities, housing and food insecurity, mental health disorders such as
postpartum depression, and anxiety (Fallin-Bennett et al., 2020; Higgins et al., 2019). Topics that
should be incorporated into the checklist include home safety, housing stability, opencommunication link, home security, and interactions between mother and other members of the
household (Goodman et al., 2019). The visit should include a socioeconomic checklist, an opioid
use questionnaire, and a maternal-child teaching assessment tool (Goodman et al., 2019). One of
the many tools to assess for NAS symptoms or complications of maternal opioid use can be used
for months after birth and should be part of the home visit assessment (Anbalagan & Mendez,
2020).
Summary and Recommendations
In summary, the literature did show that group support through multidisciplinary care
teams, home visits, and an assessment checklist are essential for mother-child well-being. It is
recommended that these three interventions be submitted for initial guideline development of a
program for postpartum women with OUD who were treated with MAT during pregnancy.
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Appendix J: GRADE Table of Evidence
Author(s): Lea Ann Quave, MSN-Ed, RN
Question: Should best evidence-based interventions be used to create a guideline compared to not using best evidence-based interventions to create a guideline to help reduce
relapse and improve the mother-child dyad for postpartum women with OUD who were treated with MAT during pregnancy? What main interventions should form the basis of a
guideline for the care of postpartum women with OUD who were treated with MAT during pregnancy after they are released from the hospital, and what will help them stay clean and
sober and on the road to recovery?
Setting: rural community in Texas Gulf Coast
Certainty assessment

№ of
studies

Study
design

Risk
of
bias

Inconsistency

Indirectness

Imprecision

Impact

Certainty

Importance

Home visits allow the health care team to “meet women
where they are” (Hodgins et al., 2019, p. 586). The
Collaborative Outreach and Adaptable Care at Hallmark
Health (COACHH) program in Massachusetts has found
check-ins one or two times a week through home visits
or phone calls to improve outcomes for mothers with
substance use disorder (Hodgins et al., 2019). The home
visits allow the provider to assess the home environment
and gain a glimpse of the everyday life of the client to
facilitate care based on observation (Hodgins et al.,
2019; Lewis et al., 2017). The Johns Hopkins University
family-based recovery model (FBR) successfully helps
mothers with OUD to remain sober by implementing a
series of step-down home visits; the client is seen in their
home at three separate 60-minute visits for the six
months of treatment, tapering to once a week visits by
the end of the first year postpartum (Hanson, Saul, &
Duryea et al., 2019). Home visits were found to decrease
risk of relapse, increase treatment retention, improve
parenting skills of the mother, decrease adverse
involvement of child welfare departments, and reduce
subsequent unintended short interval pregnancies in
postpartum women with OUD (Goodman et al., 2015).
Home visits can be supplemented with technology such
as smartphones, which have been provided to clients to
facilitate check-ins, send reminders of appointments,
complete surveys, provide education, and facilitate
communication (Sanjuan et al., 2020).

⨁⨁◯◯

CRITICAL

Other
considerations

Home visits will help reduce relapse and improve the mother-child dyad.
9

observational
not
studies
serious
a

not serious

not serious

not serious

none

LOW b
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Certainty assessment

№ of
studies

Study
design

Risk
of
bias

Inconsistency

Indirectness

Imprecision

Impact

Certainty

Importance

An integrated needs assessment has been shown to
improve outcomes for the mother-child dyad (Hodgins et
al., 2019). Ongoing assessment through documentation,
such as a checklist, provides a means for measuring
improvement or reveal downward trends; thus, improving
outcomes for postpartum women with OUD (Goodman et
al., 2019; Hodgins et al., 2019). Following a standardized
checklist can prevent the oversight of important
assessments and improve communication of needs to
other members of the healthcare team (Goodman et al.,
2019). Items that assess anxiety and stress of the
mother should be included in the checklist since high
stress situations can lead to relapse (Dworkin et al.,
2017; Fallin-Bennett et al., 2020; Hanson, Saul & Duryea
et al., 2019; Hanson, Saul, & Vanderploeg et al., 2015;
Harvey et al., 2015). Mother-child bonding and
attachment are important indicators of family dynamics;
lack of a healthy mother-child relationship may indicate
psychological issues that could lead to relapse and
should therefore be a routine assessment measure
(Hanson, Saul, & Duryea et al., 2019; Hanson, Saul, &
Vanderploeg et al., 2015; Mirick & Steenrod, 2016;
Sanjuan et al., 2020). Socioeconomic assessment
should be included in the checklist, such as lack of
transportation, unsafe housing, and food insecurities
(Lewis et al., 2017). Postpartum women with OUD
should be assessed for alcohol, tobacco, and other
substance use, partner violence, food insecurities,
housing and food insecurity, mental health disorders
such as postpartum depression, and anxiety (FallinBennett et al., 2020; Higgins et al., 2019). Topics that
should be incorporated into the checklist include home
safety, housing stability, open-communication link, home
security, and interactions between mother and other
members of the household (Goodman et al., 2019). The
visit should include a socioeconomic checklist, an opioid
use questionnaire, and a maternal-child teaching
assessment tool (Goodman et al., 2019). One of the
many tools to assess for NAS symptoms or
complications of maternal opioid use can be used for
months after birth and should be part of the home visit
assessment (Anbalagan & Mendez, 2020).

⨁⨁◯◯

CRITICAL

Other
considerations

A visit checklist used by the care professional will help reduce relapse and improve the mother-child dyad.
10

observational
not
studies
serious
a

not serious

not serious

not serious

none

LOW

b
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Certainty assessment

№ of
studies

Study
design

Risk
of
bias

Inconsistency

Indirectness

Imprecision

Impact

Certainty

Importance

Collaborative care of the postpartum women with OUD
must address physical, psychological, and
socioeconomic issues such as postnatal health care for
the mother and infant, substance use, pharmacological
MAT adherence, housing instability, food insecurity,
intimate partner violence, mother-child bonding, and
mental health disorders (Hanson, Saul, & Duryea et al.,
2019; Hanson, Saul, & Vanderploeg et al., 2015; Harvey
et al., 2015; Higgins et al., 2019; Hodgins et al., 2019).
Goodman et al. (2015) found that better outcomes where
achieved when care for mothers with substance abuse
were treated in a multidisciplinary manner which included
women’s health care, addiction therapy, health
promotion for mother and child, and education to meet
the learning needs of the mother. In addition to
collaborative management of the mother,
interdisciplinary team care for the infant with neonatal
abstinence syndrome, or the infant with a propensity for
complications of maternal opioid use, has shown to
improve health outcomes (Anbalagan & Mendez, 2020).
Social services and family counselors on the
collaborative care team provide resource allocation to
match client needs, as well as parenting education that
can motivate the postpartum woman to remain sober
(Holbrook & Nguyen, 2015). Increased involvement of
social service and child welfare should be initiated for
children at risk (Holbrook & Nguyen, 2015).

⨁⨁◯◯

CRITICAL

Other
considerations

A multidisciplinary team approach will help reduce relapse and improve the mother-child dyad.
11

observational
not
studies
serious
a

not serious

not serious

not serious

none

CI: Confidence interval

Explanations
a.
b.

Bias is difficult to ascertain in observational studies researching mental health or population health.
Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

LOW

b
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Appendix K: Clinical Practice Guidelines Evidence to Decision (EtD) Framework

CLINICAL PRACTICE GUIDELINES EVIDENCE TO DECISION (EtD)
RECOMMENDATIONS FOR PWOUD CHECKLIST
Domain: Scope and purpose
The overall objective of the initial guideline is to use three main best evidence-based practice
interventions as the foundation to construct comprehensive guidelines for a 12-month follow-up
program for the care of postpartum women with opioid use disorder (OUD) who were treated with
medication assisted treatment (MAT) during pregnancy. It has been shown that mothers who use
opioids are less likely to develop healthy attachment relationships with infants and children,
leading to an increase in behavioral and emotional issues for the child that can have long-lasting
effects (Romanowicz et al., 2019). The overarching goal of the program will be to decrease the
rate of relapse in postpartum women and improve the parental relationship between the mother
and child. The question guiding this program design project is as follows: Will the use of an
interprofessional multidisciplinary team, home visits, and the use of standardized checklists
provide a sufficient foundation to facilitate the development of clinical practice guidelines for a
postpartum follow-up program for women treated for opioid use disorder during pregnancy with
MAT? The comprehensive program guidelines will be used to provide care to postpartum women
with OUD who were treated with MAT during pregnancy in a rural community on the Texas Gulf
Coast.
PWOUD Checklist Items:
1.
The overall objective(s) of the guideline is (are) specifically described.
2.
The health question(s) covered by the guideline is (are) specifically described.
3.
The population (patients, public, etc.) to whom the guideline is meant to apply is
specifically described.
Domain: Stakeholder involvement
The guideline development group includes an anonymous panel of experts from multiple
disciplines that hold an interest in the care of the target population. Panel members include
professionals in the following specialties: mental health, addiction services, registered nurse
leadership, social work, women’s health, pediatrics, and community services. The views of the
guideline development group will be sought during the guideline development process. The views
of the ultimate target population, postpartum women with OUD who were treated with MAT
during pregnancy, were evaluated during the review of the evidence; views and preferences of the
target population will be sought during implementation of the following comprehensive program
design.
PWOUD Checklist Items:
4.
The guideline development group includes individuals from all the relevant professional
groups.
5.
The views and preferences of the target population (patients, public, etc.) have been
sought.
6.
The target users of the guideline are clearly defined.
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Domain: Rigor of development
A rapid review literature review was completed using the online EBSCOhost database provided
through the Margarett and Herman Brown Library at Abilene Christian University. Rapid reviews
are endorsed by the World Health Organization (WHO) and are well-suited for time sensitive tasks
such as guideline development and decision-making regarding recommendations as they provide
concise and focused information on relevant topics and are intended to address specific end-users
rather than contribute to general knowledge (Hartling et al., 2017; Hartling et al., 2015; Langlois
et al., 2018; Tricco et al., 2017). The goal of this rapid literature review is to organize evidence to
support the findings of a previously completed systematic literature review to determine best
evidence-based practice for the follow-up care of postpartum women with opioid use disorder
(OUD) who were treated with MAT during pregnancy. The evidence was supported by a review of
existing guidelines from various like-minded organizations providing care to the target population.
The question guiding this literature review was: What main interventions should form the basis of
a guideline for the care of postpartum women with OUD who were treated with MAT during
pregnancy after they are released from the hospital, and what will help them remain abstinent and
on the road to recovery?
The following terms were used for the initial search: postpartum, home visits “or” checklist “or”
multidisciplinary team, opioid, relapse. Filters used were full text, scholarly peer reviewed journal
articles, academic journals, substance abuse, and pregnancy. Publications between the years 2015
and 2020 were included. The initial search produced 9,729 results. After filters were added, 31
articles remained. Duplicate articles were excluded, as were articles published in countries other
than the United States and articles that did not provide relevant information; 13 articles remained
and were included in the review.
Review of Literature. Collaborative multidisciplinary management. Collaborative care of the
postpartum women with OUD must address physical, psychological, and socioeconomic issues
such as postnatal health care for the mother and infant, substance use, pharmacological MAT
adherence, housing instability, food insecurity, intimate partner violence, mother-child bonding,
and mental health disorders (Hanson, Saul, & Duryea et al., 2019; Hanson, Saul, & Vanderploeg
et al., 2015; Harvey et al., 2015; Higgins et al., 2019; Hodgins et al., 2019). Goodman et al.
(2015) found that better outcomes where achieved when care for mothers with substance abuse
were treated in a multidisciplinary manner which included women’s health care, addiction
therapy, health promotion for mother and child, and education to meet the learning needs of the
mother. In addition to collaborative management of the mother, interdisciplinary team care for the
infant with neonatal abstinence syndrome, or the infant with a propensity for complications of
maternal opioid use, has shown to improve health outcomes (Anbalagan & Mendez, 2020). Social
services and family counselors on the collaborative care team provide resource allocation to
match client needs, as well as parenting education that can motivate the postpartum woman to
remain sober (Holbrook & Nguyen, 2015). Increased involvement of social service and child
welfare should be initiated for children at risk (Holbrook & Nguyen, 2015).
In-home visits. Home visits allow the health care team to “meet women where they are” (Hodgins
et al., 2019, p. 586). The Collaborative Outreach and Adaptable Care at Hallmark Health
(COACHH) program in Massachusetts has found check-ins one or two times a week through home
visits or phone calls to improve outcomes for mothers with substance use disorder (Hodgins et al.,
2019). The home visits allow the provider to assess the home environment and gain a glimpse of
the everyday life of the client to facilitate care based on observation (Hodgins et al., 2019; Lewis
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et al., 2017). The Johns Hopkins University family-based recovery model (FBR) successfully helps
mothers with OUD to remain sober by implementing a series of step-down home visits; the client is
seen in their home at three separate 60-minute visits for the six months of treatment, tapering to
once a week visits by the end of the first year postpartum (Hanson, Saul, & Duryea et al., 2019).
Home visits were found to decrease risk of relapse, increase treatment retention, improve
parenting skills of the mother, decrease adverse involvement of child welfare departments, and
reduce subsequent unintended short interval pregnancies in postpartum women with OUD
(Goodman et al., 2015). Home visits can be supplemented with technology such as smartphones,
which have been provided to clients to facilitate check-ins, send reminders of appointments,
complete surveys, provide education, and facilitate communication (Sanjuan et al., 2020).
Assessment checklists. An integrated needs assessment has been shown to improve outcomes for
the mother-child dyad (Hodgins et al., 2019). Ongoing assessment through documentation, such as
a checklist, provides a means for measuring improvement or reveal downward trends; thus,
improving outcomes for postpartum women with OUD (Goodman et al., 2019; Hodgins et al.,
2019). Following a standardized checklist can prevent the oversight of important assessments and
improve communication of needs to other members of the healthcare team (Goodman et al., 2019).
Items that assess anxiety and stress of the mother should be included in the checklist since highstress situations can lead to relapse (Dworkin et al., 2017; Fallin-Bennett et al., 2020; Hanson,
Saul & Duryea et al., 2019; Hanson, Saul, & Vanderploeg et al., 2015; Harvey et al., 2015).
Mother-child bonding and attachment are important indicators of family dynamics; lack of a
healthy mother-child relationship may indicate psychological issues that could lead to relapse and
should therefore be a routine assessment measure (Hanson, Saul, & Duryea et al., 2019; Hanson,
Saul, & Vanderploeg et al., 2015; Mirick & Steenrod, 2016; Sanjuan et al., 2020). Socioeconomic
assessment should be included in the checklist, such as lack of transportation, unsafe housing, and
food insecurities (Lewis et al., 2017). Postpartum women with OUD should be assessed for
alcohol, tobacco, and other substance use, partner violence, food insecurities, housing and food
insecurity, mental health disorders such as postpartum depression, and anxiety (Fallin-Bennett et
al., 2020; Higgins et al., 2019). Topics that should be incorporated into the checklist include home
safety, housing stability, open-communication link, home security, and interactions between
mother and other members of the household (Goodman et al., 2019). The visit should include a
socioeconomic checklist, an opioid use questionnaire, and a maternal-child teaching assessment
tool (Goodman et al., 2019). One of the many tools to assess for NAS symptoms or complications
of maternal opioid use can be used for months after birth and should be part should be a part of
the home visit assessment (Anbalagan & Mendez, 2020).
This guideline has been reviewed by the author and is being presented for review by an expert
panel of stakeholders. This presentation is the initial review of the guideline. The guideline will be
updated throughout the review process based on recommendations by the expert panel. Once
consensus on acceptance of the guideline has been reached, it will be used as the basis of a formal,
comprehensive guideline development project for a program to treat the target population.
PWOUDChecklist Items:
7.
Systematic methods were used to search for evidence.
8.
The criteria for selecting the evidence are clearly described.
9.
The strengths and limitations of the body of evidence are clearly described.
10.
The methods for formulating the recommendations are clearly described.
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11.
The health benefits, side effects, and risks have been considered in formulating the
recommendations.
12.
There is an explicit link between the recommendations and the supporting evidence.
13.
The guideline has been externally reviewed by experts prior to its publication.
14.
A procedure for updating the guideline is provided.
Domain: Clarity of presentation
The results of all the reviewed articles and guidelines showed the top three best evidence-based
practice interventions with good results were collaborative multidisciplinary management, inhome visits, and assessment checklists to guide care. In summary, the literature did show that
group support through multidisciplinary care teams, home visits, and an assessment checklist are
essential for mother-child well-being. It is recommended that these three interventions be
submitted for initial guideline development of a program for postpartum women with OUD who
were treated with MAT during pregnancy.

PWOUD Checklist Items:
15.
The recommendations are specific and unambiguous.
16.
The different options for management of the condition or health issue are clearly presented.
17.
Key recommendations are easily identifiable.
Domain: Applicability
Items in the domain of applicability are not addressed in this guideline. Applicability items will be
addressed during the development of a formal, comprehensive guideline development project for a
program to treat the target population.

PWOUD Checklist Items (will be graded as neutral on checklist):
18.
The guideline describes facilitators and barriers to its application.
19.
The guideline provides advice and/or tools on how the recommendations can be put into
practice.
20.
The potential resource implications of applying the recommendations have been
considered.
21.
The guideline presents monitoring and/or auditing criteria.
Domain: Editorial independence
There were no funding bodies for this guideline development. There were no competing interests
between guideline development group members.

PWOUDChecklist Items:
22.
The views of the funding body have not influenced the content of the guideline.
23.
Competing interests of guideline development group members have been recorded and
addressed.

